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NON - NATURALLY OCCURRING PORCINE sisting of SEQ ID NO : 2 , 4 , 6 , 8 , 10 , 12 , 14 , 16 , 18 , 20 , 22 , 
REPRODUCTIVE AND RESPIRATORY 24 , 26 , 28 , 30 , 32 , 34 , 36 , 38 , 40 , and 42. In some 
SYNDROME VIRUS ( PRRSV ) AND embodiments , the nucleic acid encodes , respectively , a poly 
METHODS OF USING peptide having an amino acid sequence selected from the 
group consisting of SEQ ID NO : 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 , 19 , 
CROSS REFERENCE TO RELATED 21 , 23 , 25 , 27 , 29 , 31 , 33 , 35 , 37 , 39 , 41 and 43. A virus 
APPLICATIONS particle comprising the PPRSV - CON nucleic acid described 
herein . A composition comprising the nucleic acid described 
This application is a continuation application of U.S. herein and a pharmaceutically acceptable carrier . A compo 
patent application Ser . No. 15 / 127,931 filed on Sep. 21 , 10 sition comprising the virus particle described herein and a 
2016 , which is a U.S. National Application from PCT pharmaceutically acceptable carrier . The composition 
Application No. PCT / IB2015 / 052214 filed on Mar. 25 , described herein , further comprising an adjuvant . 
2015 , which claims the benefit of priority under A PRRSV - CON polypeptide is provided , where the poly 
35 U.S.C. § 119 ( e ) to U.S. Application No. 61 / 968,465 , filed peptide has at least 95 % ( e.g. , at least 99 % ) sequence 
Mar. 21 , 2014 . 15 identity to a sequence selected from the group consisting of 
SEQ ID NO : 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 , 19 , 21 , 23 , 25 , 27 , 29 , 
FEDERALLY SPONSORED RESEARCH OR 31 , 33 , 35 , 37 , 39 , 41 and 43. In some embodiments , the 
DEVELOPMENT polypeptide has a sequence selected from the group con 
sisting of SEQ ID NO : 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 , 19 , 21 , 23 , 
This invention was made with government support under 2025 , 27 , 29 , 31 , 33 , 35 , 37 , 39 , 41 and 43. In some embodi 
2013-31100-06031 , 2012-31100-06031 , and 2008-5562 ments , the polypeptide is encoded by a nucleic acid , respec 
19132 awarded by United States Department of Agriculture , tively , having a sequence selected from the group consisting 
National Institute of Food and Agriculture . The government of SEQ ID NOs : 4 , 6 , 8 , 10 , 12 , 14 , 16 , 18 , 20 , 22 , 24 , 26 , 
has certain rights in the invention . 28 , 30 , 32 , 34 , 36 , 38 , 40 , or 42. A virus particle comprising 
25 the PPRSV - CON polypeptide described herein . A composi 
TECHNICAL FIELD tion comprising the polypeptide described herein and a 
pharmaceutically acceptable carrier . A composition com 
This disclosure generally relates to a non - naturally occur prising the virus particle described herein and a pharmaceu 
ring porcine reproductive and respiratory syndrome virus tically acceptable carrier . The composition described herein , 
( PRRSV ) and methods of using . 30 further comprising an adjuvant . 
A method for eliciting an immune response to PPRSV in 
BACKGROUND a porcine is provided . Such a method typically includes 
administering , to a porcine : ( i ) an effective amount of any of 
Current porcine reproductive and respiratory syndrome the nucleic acids described herein ; ( ii ) an effective amount 
virus ( PRRSV ) vaccines are not adequately effective for 35 of any of the polypeptides described herein ; ( iii ) an effective 
control and eradication of porcine reproductive and respi amount of any of the virus particles described herein ; or ( iv ) 
ratory syndrome ( PRRS ) . The main limitation of the current an effective amount of any of the compositions described 
PRRSV vaccines is their sub - optimal coverage against herein . Representative routes of administration include , 
divergent PRRSV strains . Thus far , all commercial PRRSV without limitation , intramuscularly , intraperitoneally , and 
vaccines are formulated using natural PRRSV strains , but 40 orally . 
the substantial genetic variation among the PRRSV strains is A method for treating or preventing PPRS in a porcine is 
the biggest obstacle for the development of a broadly provided . Such a method typically includes administering , 
protective PRRSV vaccine . to a porcine : ( i ) an effective amount of any of the nucleic 
acids described herein ; ( ii ) an effective amount of any of the 
SUMMARY 45 polypeptides described herein ; ( iii ) an effective amount of 
any of the virus particles described herein ; or ( iv ) an 
This disclosure provides a non - naturally occurring por effective amount of any of the compositions described 
cine reproductive and respiratory syndrome virus ( PRRSV ) herein . Representative routes of administration include , 
and methods of making and using the non - naturally occur without limitation , intramuscularly , intraperitoneally , and 
ring PRRSV . 50 orally . 
A PRRSV - CON nucleic acid is provided , where the Unless otherwise defined , all technical and scientific 
nucleic acid has at least 50 % sequence identity ( e.g. , at least terms used herein have the same meaning as commonly 
75 % , at least 95 % , or at least 99 % sequence identity ) to SEQ understood by one of ordinary skill in the art to which the 
ID NO : 1 . In some embodiment , the nucleic acid has the methods and compositions of matter belong . Although meth 
sequence shown in SEQ ID NO : 1 . A virus particle compris- 55 ods and materials similar or equivalent to those described 
ing the PPRSV - CON nucleic acid described herein . A com herein can be used in the practice or testing of the methods 
position comprising the PPRSV - CON nucleic acid described and compositions of matter , suitable methods and materials 
herein and a pharmaceutically acceptable carrier . A compo are described below . In addition , the materials , methods , and 
sition comprising the virus particle described herein and a examples are illustrative only and not intended to be limit 
pharmaceutically acceptable carrier . The compositions 60 ing . All publications , patent applications , patents , and other 
described herein , further comprising an adjuvant . references mentioned herein are incorporated by reference in 
A PRRSV - CON nucleic acid also is provided , where the their entirety . 
nucleic acid has at least 95 % ( e.g. , at least 99 % ) sequence 
identity to a sequence selected from the group consisting of DESCRIPTION OF DRAWINGS 
SEQ ID NO : 2 , 4 , 6 , 8 , 10 , 12 , 14 , 16 , 18 , 20 , 22 , 24 , 26 , 28 , 65 
30 , 32 , 34 , 36 , 38 , 40 , and 42. In some embodiments , the FIG . 1 , Panel ( A ) is a phylogenetic tree constructed from 
nucleic acid has a sequence selected from the group con a set of 60 PRRSV full - genome sequences . These 60 
US 10,738,088 B2 
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PRRSV genomes are classified into 4 sub - groups . The challenge as determined by a commercial , universal RT 
locations of the viruses involved in the cross - protection qPCR ( Tetracore Inc. , Rockville , Md . ) . Panel ( D ) shows the 
experiments are indicated by the arrows . FIG . 1 , Panel ( B ) 16244B - specific RNA levels as determined by a differential 
is a graph showing the genetic distances among natural RT - qPCR developed in - house . 
PRRSV strains and the genetic distance from the PRRSV- 5 
CON described herein to the natural PRRSV strains . The DETAILED DESCRIPTION 
lower and upper boundaries of the box indicate the 25th and 
75th percentile respectively . The solid line within the box A non - naturally occurring porcine reproductive and respi 
represents the median . Whiskers above and below the box ratory syndrome virus ( PRRSV ) genome was designed using 
indicate the minimum and maximum of the data . 10 a large set of genomic sequences of PRRSV isolates , which 
FIG . 2 shows the generation and characterization of the represents the widest genetic diversity of PRRSV strains 
PRRSV - CON virus . Panel ( A ) is a schematic showing the circulating in U.S. swine herds . The non - naturally occurring 
strategy to construct the PRRSV - CON full - genome cDNA PRRSV genome was designed so that it has a high degree of 
clone . The upper half of Panel ( A ) depicts the schematic genetic similarity to the PRRSV field - isolates studied when 
representation of the viral genome , together with the unique 15 compared to any single , naturally occurring PRRSV strain . 
restriction enzyme sites used for cloning purposes . The Porcine reproductive and respiratory syndrome ( PRRS ) is 
horizontal black lines , with the letters A - D on top , represent one of the most economically important diseases in swine . 
the DNA fragments that were synthesized . The numbers Clinical signs of the disease include reproductive failure in 
inside the parenthesis below the lines indicate the length ( in pregnant sows and respiratory disorder in young pigs . The 
nucleotides ) of each corresponding fragments . OT7 repre- 20 disease is more severe when animals are co - infected with 
sents the T7 RNA polymerase promoter . Individual DNA other pathogens . The annual loss to the US swine industry 
fragments of the genome were sequentially inserted into the was estimated to be about $ 560 million in 2005 and about 
shuttle vector ( shown in the lower half of Panel ( A ) ) in the $ 640 million in 2011 . 
order of fragment A to fragment D. Panel ( B ) are photo The causative agent of PRRS is an RNA virus named 
graphs showing the reactivity of the indicated viruses with 25 PRRS virus ( PRRSV ) . PRRSV is classified into two major 
different PRRSV - specific monoclonal antibodies . MARC genotypes : European ( Type 1 ) and North American ( Type 2 ) . 
145 cells were mock infected or infected with PRRSV - CON There is limited cross - protection between these two geno 
or PRRSV wild type strain , FL12 . At 48 hours post - infec types . Considerable genetic variation exists among PRRSV 
tion , the cells were stained with antibodies specific to the isolates within each of these genotypes . Importantly , genetic 
viral nucleocapsid protein ( N protein ; bottom row of pho- 30 divergence has been shown to occur when a PRRSV strain 
tographs ) or to the viral nonstructural protein 1 beta ( nsplb ; is serially passed from pig to pig . This leads to co - circulation 
top row of photographs ) . Panel ( C ) shows the plaque mor of multiple PRRSV variants within one herd or even within 
phology of the viruses in MARC - 145 cells . Panel ( D ) shows one animal that is persistently infected with PRRSV . 
a multiple step growth curve . MARC - 145 cells were PRRSV vaccines have been in use since 1994. There are 
infected with the indicated viruses at a multiplicity of 35 two types of PRRSV vaccines currently available in the 
infection ( MOI ) of 0.01 . At different timepoints post - infec market ; modified - live and inactivated vaccines . In addition , 
tion ( p.i. ) , culture supernatant was collected and viral titer several subunit vaccines against PRRSV are being tested in 
was determined by titration on MARC - 145 cells . different laboratories worldwide , but none have been 
FIG . 3 is data demonstrating replication of the PRRSV licensed for clinical application . Currently , PRRSV vaccines 
CON in pigs . Panel ( A ) shows the rectal temperature mea- 40 are prepared using naturally occurring PRRSV strains as the 
sured daily from 1 day before infection to 13 days post vaccine immunogens . The current PRRSV vaccines are not 
infection ( days p.i. ) . Panel ( B ) shows the average daily adequately effective for control and eradication of PRRS ; 
weight gain ( ADWG ) within 14 days after inoculation . they provide acceptable levels of homologous protection but 
Panel ( C ) shows the viremia levels , determined by a com they fail to provide consistent heterologous cross - protection . 
mercial , universal RT - qPCR ( Tatracore Inc. , Rockville , 45 Extensive genetic diversity among PRRSV isolates is the 
Md . ) . Panel ( D ) shows the levels of antibody response after main reason behind the sub - optimal heterologous protection 
inoculation , determined by IDEXX ELISA ; the horizontal of the current PRRSV vaccines . 
dotted line indicates the cut - off of the assay . The non - naturally occurring PRRSV - CON described 
FIG . 4 is data demonstrating cross - protection provided by herein confers superior cross - protective against different 
the PRRSV - CON described herein against the PRRSV- 50 heterologous PRRSV strains , as compared to the PRRSV 
strain , MN - 184 . Panel ( A ) shows the average daily weight wild type strain FL12 . Thus , the PRRSV - CON described 
gain ( ADWG ) within 15 days after challenge - infection . herein can be used to formulate a universal PRRSV vaccine . 
Panel ( B ) shows the viremia levels after challenge deter In addition , the PRRSV - CON described herein provides an 
mined by a commercial , universal RT - qPCR ( Tetracore Inc. , important tool to study the mechanism of heterologous 
Rockville , Md . ) . Panel ( C ) shows total viral RNA levels in 55 protection against divergent PRRSV strains . 
different tissues collected at 15 days post - challenge as Nucleic Acids and Polypeptides 
determined by a commercial , universal RT - qPCR ( Tetracore The PRRSV genome encodes at least 22 proteins ; 14 
Inc. , Rockville , Md . ) . Panel ( D ) shows the MN - 184 - specific non - structural proteins and 8 structural proteins . A nucleic 
RNA levels as determined by a differential RT - qPCR devel acid is provided herein that encodes for a non - naturally 
oped in - house . 60 occurring PRRSV . See SEQ ID NO : 1 for the genomic 
FIG . 5 is data demonstrating cross - protection against sequence of PRRSV - CON . The non - naturally occurring 
PRRSV strain , 16244B . Panel ( A ) shows the average daily PRRSV described herein possesses the highest degree of 
weight gain ( ADWG ) within 15 days after challenge - infec genetic identity with the naturally occurring PRRSV iso 
tion . Panel ( B ) shows the viremia levels after challenge lates . The PRRSV - CON genomic nucleic acid provided 
infection determined by a commercial , universal RT - qPCR 65 herein ( i.e. , SEQ ID NO : 1 ) encodes for a number of different 
( Tetracore Inc. , Rockville , Md . ) . Panel ( C ) shows total viral polypeptides . For example , the nucleic acid sequence shown 
RNA levels in different tissues collected at 15 days post in SEQ ID NO : 2 encodes for the polypeptide sequence 
US 10,738,088 B2 
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having the amino acid sequence shown in SEQ ID NO : 3 ; the differ in sequence from any of SEQ ID NOs : 3 , 5 , 7 , 9 , 11 , 
nucleic acid sequence shown in SEQ ID NO : 4 encodes for 13 , 15 , 17 , 19 , 21 , 23 , 25 , 27 , 29 , 31 , 33 , 35 , 37 , 39 , 41 or 
the polypeptide sequence having the amino acid sequence 43 , can have at least 80 % sequence identity ( e.g. , at least 
shown in SEQ ID NO : 5 ; the nucleic acid sequence shown in 81 % , 82 % , 83 % , 84 % , 85 % , 86 % , 87 % , 88 % , 89 % , 90 % , 
SEQ ID NO : 6 encodes for the polypeptide sequence having 5 91 % , 92 % , 93 % , 94 % , 95 % , 96 % , 97 % , 98 % , or 99 % 
the amino acid sequence shown in SEQ ID NO : 7 ; the nucleic sequence identity ) to any of SEQ ID NOs : 3 , 5 , 7 , 9 , 11 , 13 , 
acid sequence shown in SEQ ID NO : 8 encodes for the 15 , 17 , 19 , 21 , 23 , 25 , 27 , 29 , 31 , 33 , 35 , 37 , 39 , 41 or 43 . 
polypeptide sequence having the amino acid sequence In calculating percent sequence identity , two sequences 
shown in SEQ ID NO : 9 ; the nucleic acid sequence shown in are aligned and the number of identical matches of nucleo 
SEQ ID NO : 10 encodes for the polypeptide sequence having 10 tides or amino acid residues between the two sequences is 
the amino acid sequence shown in SEQ ID NO : 11 ; the determined . The number of identical matches is divided by 
nucleic acid sequence shown in SEQ ID NO : 12 encodes for the length of the aligned region ( i.e. , the number of aligned 
the polypeptide sequence having the amino acid sequence nucleotides or amino acid residues ) and multiplied by 100 to 
shown in SEQ ID NO : 13 ; the nucleic acid sequence shown arrive at a percent sequence identity value . It will be 
in SEQ ID NO : 14 encodes for the polypeptide sequence 15 appreciated that the length of the aligned region can be a 
having the amino acid sequence shown in SEQ ID NO : 15 ; portion of one or both sequences up to the full - length size of 
the nucleic acid sequence shown in SEQ ID NO : 16 encodes the shortest sequence . It also will be appreciated that a single 
for the polypeptide sequence having the amino acid sequence can align with more than one other sequence and 
sequence shown in SEQ ID NO : 17 ; the nucleic acid hence , can have different percent sequence identity values 
sequence shown in SEQ ID NO : 18 encodes for the poly- 20 over each aligned region . 
peptide sequence having the amino acid sequence shown in The alignment of two or more sequences to determine 
SEQ ID NO : 19 ; the nucleic acid sequence shown in SEQ ID percent sequence identity can be performed using the com 
NO : 20 encodes for the polypeptide sequence having the puter program ClustalW and default parameters , which 
amino acid sequence shown in SEQ ID NO : 21 ; the nucleic allows alignments of nucleic acid or polypeptide sequences 
acid sequence shown in SEQ ID NO : 22 encodes for the 25 to be carried out across their entire length ( global align 
polypeptide sequence having the amino acid sequence ment ) . Chenna et al . , 2003 , Nucleic Acids Res . , 31 ( 13 ) : 
shown in SEQ ID NO : 23 ; the nucleic acid sequence shown 3497-500 . Clustal W calculates the best match between a 
in SEQ ID NO : 24 encodes for the polypeptide sequence query and one or more subject sequences , and aligns them 
having the amino acid sequence shown in SEQ ID NO : 25 ; so that identities , similarities and differences can be deter 
the nucleic acid sequence shown in SEQ ID NO : 26 encodes 30 mined . Gaps of one or more residues can be inserted into a 
for the polypeptide sequence having the amino acid query sequence , a subject sequence , or both , to maximize 
sequence shown in SEQ ID NO : 27 ; the nucleic acid sequence alignments . For fast pairwise alignment of nucleic 
sequence shown in SEQ ID NO : 28 encodes for the poly acid sequences , the default parameters can be used ( i.e. , 
peptide sequence having the amino acid sequence shown in word size : 2 ; window size : 4 ; scoring method : percentage ; 
SEQ ID NO : 29 ; the nucleic acid sequence shown in SEQ ID 35 number of top diagonals : 4 ; and gap penalty : 5 ) ; for an 
NO : 30 encodes for the polypeptide sequence having the alignment of multiple nucleic acid sequences , the following 
amino acid sequence shown in SEQ ID NO : 31 ; the nucleic parameters can be used : gap opening penalty : 10.0 ; gap 
acid sequence shown in SEQ ID NO : 32 encodes for the extension penalty : 5.0 ; and weight transitions : yes . For fast 
polypeptide sequence having the amino acid sequence pairwise alignment of polypeptide sequences , the following 
shown in SEQ ID NO : 33 ; the nucleic acid sequence shown 40 parameters can be used : word size : 1 ; window size : 5 ; 
in SEQ ID NO : 34 encodes for the polypeptide sequence scoring method : percentage ; number of top diagonals : 5 ; and 
having the amino acid sequence shown in SEQ ID NO : 35 ; gap penalty : 3. For multiple alignment of polypeptide 
the nucleic acid sequence shown in SEQ ID NO : 36 encodes sequences , the following parameters can be used : weight 
for the polypeptide sequence having the amino acid matrix : blosum ; gap opening penalty : 10.0 ; gap extension 
sequence shown in SEQ ID NO : 37 ; the nucleic acid 45 penalty : 0.05 ; hydrophilic gaps : on ; hydrophilic residues : 
sequence shown in SEQ ID NO : 38 encodes for the poly Gly , Pro , Ser , Asn , Asp , Gin , Glu , Arg , and Lys ; and 
peptide sequence having the amino acid sequence shown in residue - specific gap penalties : on . ClustalW can be run , for 
SEQ ID NO : 39 ; the nucleic acid sequence shown in SEQ ID example , at the Baylor College of Medicine Search 
NO : 40 encodes for the polypeptide sequence having the Launcher website or at the European Bioinformatics Insti 
amino acid sequence shown in SEQ ID NO : 41 ; and the 50 tute website on the World Wide Web . 
nucleic acid sequence shown in SEQ ID NO : 42 encodes for Changes can be introduced into a nucleic acid molecule 
the polypeptide sequence having the amino acid sequence ( e.g. , SEQ ID NO : 1 or any of SEQ ID NOs : 2 , 4 , 6 , 8 , 10 , 12 , 
shown in SEQ ID NO : 43 . 14 , 16 , 18 , 20 , 22 , 24 , 26 , 28 , 30 , 32 , 34 , 36 , 38 , 40 , or 42 ) , 
As used herein , nucleic acids can include DNA and RNA , thereby leading to changes in the amino acid sequence of the 
and includes nucleic acids that contain one or more nucleo- 55 encoded polypeptide ( e.g. , SEQ ID NOs : 3 , 5 , 7 , 9 , 11 , 13 , 
tide analogs or backbone modifications . A nucleic acid can 15 , 17 , 19 , 21 , 23 , 25 , 27 , 29 , 31 , 33 , 35 , 37 , 39 , 41 or 43 ) . 
be single stranded or double stranded , which usually For example , changes can be introduced into nucleic acid 
depends upon its intended use . Nucleic acids and polypep coding sequences using mutagenesis ( e.g. , site - directed 
tides that differ from SEQ ID NOs : 1-43 also are provided . mutagenesis , PCR - mediated mutagenesis ) or by chemically 
Nucleic acids that differ in sequence from SEQ ID NO : 1 or 60 synthesizing a nucleic acid molecule having such changes . 
any of SEQ ID NOs : 2 , 4 , 6 , 8 , 10 , 12 , 14 , 16 , 18 , 20 , 22 , 24 , Such nucleic acid changes can lead to conservative and / or 
26 , 28 , 30 , 32 , 34 , 36 , 38 , 40 , or 42 can have at least 80 % non - conservative amino acid substitutions at one or more 
sequence identity ( e.g. , at least 81 % , 82 % , 83 % , 84 % , 85 % , amino acid residues . A “ conservative amino acid substitu 
86 % , 87 % , 88 % , 89 % , 90 % , 91 % , 92 % , 93 % , 94 % , 95 % , tion ” is one in which one amino acid residue is replaced with 
96 % , 97 % , 98 % , or 99 % sequence identity ) to SEQ ID NO : 1 65 a different amino acid residue having a similar side chain 
or any of SEQ ID NOs : 2 , 4 , 6 , 8 , 10 , 12 , 14 , 16 , 18 , 20 , 22 , ( see , for example , Dayhoff et al . ( 1978 , in Atlas of Protein 
24 , 26 , 28 , 30 , 32 , 34 , 36 , 38 , 40 , or 42. Polypeptides that Sequence and Structure , 5 ( Suppl . 3 ) : 345-352 ) , which pro 
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vides frequency tables for amino acid substitutions ) , and a elements also can include introns , enhancer sequences , 
non - conservative substitution is one in which an amino acid response elements , or inducible elements that modulate 
residue is replaced with an amino acid residue that does not expression of a nucleic acid . Expression elements can be of 
have a similar side chain . bacterial , yeast , insect , mammalian , or viral origin , and 
As used herein , an " isolated ” nucleic acid molecule is a 5 vectors can contain a combination of elements from different 
nucleic acid molecule that is free of sequences that naturally origins . As used herein , operably linked means that pro 
flank one or both ends of the nucleic acid in the genome of moter or other expression element ( s ) are positioned in a 
the organism from which the isolated nucleic acid molecule vector relative to a nucleic acid in such a way as to direct or 
is derived ( e.g. , a cDNA or genomic DNA fragment pro regulate expression of the nucleic acid ( e.g. , in - frame ) . 
duced by PCR or restriction endonuclease digestion ) . Such 10 Many methods for introducing nucleic acids into host cells , 
an isolated nucleic acid molecule is generally introduced both in vivo and in vitro , are well known to those skilled in 
into a vector ( e.g. , a cloning vector , or an expression vector ) the art and include , without limitation , electroporation , 
for convenience of manipulation or to generate a fusion calcium phosphate precipitation , polyethylene glycol ( PEG ) 
nucleic acid molecule , discussed in more detail below . In transformation , heat shock , lipofection , microinjection , and 
addition , an isolated nucleic acid molecule can include an 15 viral - mediated nucleic acid transfer . 
engineered nucleic acid molecule such as a recombinant or Vectors as described herein can be introduced into a host 
a synthetic nucleic acid molecule . cell . As used herein , “ host cell ” refers to the particular cell 
As used herein , a “ purified ” polypeptide is a polypeptide into which the nucleic acid is introduced and also includes 
that has been separated or purified from cellular components the progeny of such a cell that carry the vector . A host cell 
that naturally accompany it . Typically , the polypeptide is 20 can be any prokaryotic or eukaryotic cell . For example , 
considered “ purified ” when it is at least 70 % ( e.g. , at least nucleic acids can be expressed in bacterial cells such as E. 
75 % , 80 % , 85 % , 90 % , 95 % , or 99 % ) by dry weight , free coli , or in insect cells , yeast or mammalian cells ( such as 
from the polypeptides and naturally occurring molecules Chinese hamster ovary cells ( CHO ) or COS cells ) . Other 
with which it is naturally associated . Since a polypeptide suitable host cells are known to those skilled in the art . 
that is chemically synthesized is , by nature , separated from 25 Nucleic acids can be detected using any number of 
the components that naturally accompany it , a synthetic amplification techniques ( see , e.g. , PCR Primer : A Labora 
polypeptide is “ purified . ” tory Manual , 1995 , Dieffenbach & Dveksler , Eds . , Cold 
Nucleic acids can be isolated using techniques routine in Spring Harbor Laboratory Press , Cold Spring Harbor , N.Y .; 
the art . For example , nucleic acids can be isolated using any and U.S. Pat . Nos . 4,683,195 ; 4,683,202 ; 4,800,159 ; and 
method including , without limitation , recombinant nucleic 30 4,965,188 ) with an appropriate pair of oligonucleotides 
acid technology , and / or the polymerase chain reaction ( e.g. , primers ) . A number of modifications to the original 
( PCR ) . General PCR techniques are described , for example PCR have been developed and can be used to detect a 
in PCR Primer : A Laboratory Manual , Dieffenbach & Dvek nucleic acid . 
sler , Eds . , Cold Spring Harbor Laboratory Press , 1995 . Nucleic acids also can be detected using hybridization . 
Recombinant nucleic acid techniques include , for example , 35 Hybridization between nucleic acids is discussed in detail in 
restriction enzyme digestion and ligation , which can be used Sambrook et al . ( 1989 , Molecular Cloning : A Laboratory 
to isolate a nucleic acid . Isolated nucleic acids also can be Manual , 2nd Ed . , Cold Spring Harbor Laboratory Press , 
chemically synthesized , either as a single nucleic acid mol Cold Spring Harbor , N.Y .; Sections 7.37-7.57 , 9.47-9.57 , 
ecule or as a series of oligonucleotides . 11.7-11.8 , and 11.45-11.57 ) . Sambrook et al . discloses suit 
Polypeptides can be purified from natural sources ( e.g. , a 40 able Southern blot conditions for oligonucleotide probes less 
biological sample ) by known methods such as DEAE ion than about 100 nucleotides ( Sections 11.45-11.46 ) . The Tm 
exchange , gel filtration , and hydroxyapatite chromatogra between a sequence that is less than 100 nucleotides in 
phy . A polypeptide also can be purified , for example , by length and a second sequence can be calculated using the 
expressing a nucleic acid in an expression vector . In addi formula provided in Section 11.46 . Sambrook et al . addi 
tion , a purified polypeptide can be obtained by chemical 45 tionally discloses Southern blot conditions for oligonucle 
synthesis . The extent of purity of a polypeptide can be otide probes greater than about 100 nucleotides ( see Sec 
measured using any appropriate method , e.g. , column chro tions 9.47-9.54 ) . The Tm between a sequence greater than 
matography , polyacrylamide gel electrophoresis , or HPLC 100 nucleotides in length and a second sequence can be 
analysis . calculated using the formula provided in Sections 9.50-9.51 
Avector containing a nucleic acid ( e.g. , a nucleic acid that 50 of Sambrook et al . 
encodes a polypeptide ) also is provided . Vectors , including The conditions under which membranes containing 
expression vectors , are commercially available or can be nucleic acids are prehybridized and hybridized , as well as 
produced by recombinant DNA techniques routine in the art . the conditions under which membranes containing nucleic 
A vector containing a nucleic acid can have expression acids are washed to remove excess and non - specifically 
elements operably linked to such a nucleic acid , and further 55 bound probe , can play a significant role in the stringency of 
can include sequences such as those encoding a selectable the hybridization . Such hybridizations and washes can be 
marker ( e.g. , an antibiotic resistance gene ) . A vector con performed , where appropriate , under moderate or high strin 
taining a nucleic acid can encode a chimeric or fusion gency conditions . For example , washing conditions can be 
polypeptide ( i.e. , a polypeptide operatively linked to a made more stringent by decreasing the salt concentration in 
heterologous polypeptide , which can be at either the N - ter- 60 the wash solutions and / or by increasing the temperature at 
minus or C - terminus of the polypeptide ) . Representative which the washes are performed . Simply by way of 
heterologous polypeptides are those that can be used in example , high stringency conditions typically include a 
purification of the encoded polypeptide ( e.g. , 6xHis tag , wash of the membranes in 0.2xSSC at 65 ° C. 
glutathione S - transferase ( GST ) Expression elements In addition , interpreting the amount of hybridization can 
include nucleic acid sequences that direct and regulate 65 be affected , for example , by the specific activity of the 
expression of nucleic acid coding sequences . One example labeled oligonucleotide probe , by the number of probe 
of an expression element is a promoter sequence . Expression binding sites on the template nucleic acid to which the probe 
10 
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has hybridized , and by the amount of exposure of an vidual prior to exposure or contraction of PRRS , thus 
autoradiograph or other detection medium . It will be readily preventing the disease or reducing the severity of disease 
appreciated by those of ordinary skill in the art that although symptoms .
any number of hybridization and washing conditions can be Methods for administering a PRRSV - CON nucleic acid , 
used to examine hybridization of a probe nucleic acid 5 polypeptide or virus particle to a porcine include , without 
molecule to immobilized target nucleic acids , it is more limitation , intramuscular ( i.m. ) , subcutaneous ( s.c. ) , or intra 
important to examine hybridization of a probe to target pulmonary routes . Methods for administering a PRRSV 
nucleic acids under identical hybridization , washing , and CON nucleic acid , polypeptide or virus particle to a porcine 
exposure conditions . Preferably , the target nucleic acids are also include , without limitation , intratracheal , transdermal , 
on the same membrane . intraocular , intranasal , inhalation , intracavity , and intrave 
A nucleic acid molecule is deemed to hybridize to a nous ( i.v. ) administration . 
nucleic acid but not to another nucleic acid if hybridization Determining an effective amount of a PRRSV - CON 
to a nucleic acid is at least 5 - fold ( e.g. , at least 6 - fold , 7 - fold , nucleic acid , polypeptide or virus particle depends upon a 
8 - fold , 9 - fold , 10 - fold , 20 - fold , 50 - fold , or 100 - fold ) greater number of factors including , for example , whether the 
than hybridization to another nucleic acid . The amount of antigen is being expressed or administered directly , the age 
hybridization can be quantitated directly on a membrane or and weight of the subject , the precise condition requiring 
from an autoradiograph using , for example , a PhosphorIm treatment and its severity , and the route of administration . 
ager or a Densitometer ( Molecular Dynamics , Sunnyvale , Based on the above factors , determining the amount and the 
Calif . ) . 20 dosing ( e.g. , the number of doses and the timing of doses ) 
Polypeptides can be detected using antibodies . Tech are within the level of skill of an ordinary artisan . 
niques for detecting polypeptides using antibodies include A composition can include a PRRSV - CON nucleic acid , 
enzyme linked immunosorbent assays ( ELISAs ) , Western polypeptide or virus particle as described herein and 
blots , immunoprecipitations and immunofluorescence . An pharmaceutically acceptable carrier . Pharmaceutically 
antibody can be polyclonal or monoclonal . An antibody 25 acceptable carriers are known in the art and include , for 
having specific binding affinity for a polypeptide can be example , buffers ( e.g. , phosphate buffered saline ( PBS ) , 
generated using methods well known in the art . The anti normal saline , Tris buffer , and sodium phosphate ) or 
body can be attached to a solid support such as a microtiter diluents . The compositions described herein can be formu 
plate using methods known in the art . In the presence of a lated as an aqueous solution , or as an emulsion , gel , solution , 
polypeptide , an antibody - polypeptide complex is formed . 30 suspension , or powder . See , for example , Remington's Phar 
Detection ( e.g. , of an amplification product , a hybridiza maceutical Sciences , 16th Ed . , Osol , ed . , Mack Publishing 
tion complex , or a polypeptide ) is usually accomplished Co. , Easton , Pa . ( 1980 ) , and Remington's Pharmaceutical 
using detectable labels . The term “ label ” is intended to Sciences , 19th Ed . , Gennaro , ed . , Mack Publishing Co. , Easton , Pa . ( 1995 ) . In addition to a pharmaceutically accept encompass the use of direct labels as well as indirect labels . 
Detectable labels include enzymes , prosthetic groups , fluo 35 able carrier , the compositions described herein also can include binders , stabilizers , preservatives , salts , excipients , rescent materials , luminescent materials , bioluminescent delivery vehicles and / or auxiliary agents . materials , and radioactive materials . In accordance with the present invention , there may be Methods of Making and Using a PRRSV - CON Virus Par employed conventional molecular biology , microbiology , 
ticle 40 biochemical , and recombinant DNA techniques within the 
Methods of constructing a virus particle from a PRRSV skill of the art . Such techniques are explained fully in the 
CON nucleic acid are known in the art and are described literature . The invention will be further described in the 
herein . As demonstrated herein , the PRRSV - CON described following examples , which do not limit the scope of the 
herein self - assembles into particles when appropriately methods and compositions of matter described in the claims . 
expressed . The PRRSV - CON can be expressed in vitro or in 45 
vivo , for example , in a host cell . In some embodiments , a EXAMPLES 
host cell can be transfected with the PRRSV - CON nucleic 
acid , or a host cell can be infected with a PRRSV - CON virus Example 1_Computational Design of the Artificial 
particle . Host cells can be , without limitation , porcine cells PRRSV - CON Genome 
( e.g. , porcine alveolar macrophage ) or African green mon- 50 
key kidney - derived cells ( e.g. , MARC - 145 ) . Virus particles Full - genome sequences of 64 PRRSV isolates originating 
can be isolated , for example , by ultracentrifugation . from the Midwestern states ( Iowa , Nebraska and Illinois ) of 
The PRRSV - CON nucleic acids , polypeptides or virus the U.S. were sequenced using the Roche 454 - GS - FLX 
particles described herein can be used to generate , enhance sequencing technology . In addition , more than 20 full 
or modulate the immune response of a porcine . Such meth- 55 genome sequences of PRRSV isolates originating from the 
ods typically include administering a PRRSV - CON nucleic U.S. were collected from GenBank . After removing redun 
acid , polypeptide or virus particle described herein to a dant sequences , a final set of 60 full - genome sequences of 
porcine in an amount sufficient to generate an immune PRRSV was attained . The 60 PRRSV full - genome 
response . As used herein , an “ immune response ” refers to sequences were aligned using the MUSCLE program ( Edgar 
the reaction elicited in an individual following administra- 60 RC , 2004 , BMC Bioinform . , 5 : 113 ) . After that , a consensus 
tion of a PRRSV - CON nucleic acid , polypeptide or virus genome sequence ( PRRSV - CON ) was generated by select 
particle as described herein . Immune responses can include , ing the most common nucleotide found at each position of 
for example , an antibody response or a cellular response the viral genome , using the Jalview program . Phylogenetic 
( e.g. , a cytotoxic T - cell response ) . A PRRSV - CON nucleic analysis shows that the PRRSV - CON genome locates right 
acid , polypeptide or virus particle can be used to prevent 65 at the center of the phylogenetic tree . See FIG . 1A . Conse 
PRRS in porcine , e.g. , as a prophylactic vaccine , or to quently , the pairwise genetic distance from PRRSV - CON to 
establish or enhance immunity to PRRS in a healthy indi the naturally occurring PRRSV strains is significantly 
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shorter than the distance from any one naturally occurring Example 4 — the PRRSV - CON Virus can Infect 
PRRSV strains to each other ( p < 0.0001 ) . See FIG . 1B . Pigs as Efficiently as the Natural PRRSV Strain 
Example 2 — Generation of an Infectious A total of 18 PRRSV - seronegative , 3 week - old pigs were 
PRRSV - CON Virus 5 purchased from the University of Nebraska research farm . 
The pigs were randomly assigned into 3 experimental 
It is generally difficult to accurately determine the groups ; each group was housed in a separate room in the 
sequence at 5 ' and 3 ' ends of a viral genome . Thus , we Biosecurity Level - 2 Animal Research Facilities at UNL , 
realized that the sequences at the 5 ' and 3 ' untranslated following the regulations established by the Institutional 
regions ( UTRs ) of the naturally occurring PRRSV genomes 10 Animal Care and Use Committee . Pigs in group 1 were 
analyzed in Example 1 may not be accurate . To increase the injected with PBS to act as the control . Pigs in groups 2 and 
change of recovering infectious virus , we replaced the 5 ' and 3 were inoculated intramuscularly with 105.0 TCID50 of 
3'UTRs of the PRRSV - CON genome with the 5 ' and 3 ' UTRs PRRSV - CON and PRRSV strain FL12 , respectively . The 
of the infectious cDNA clone FL12 ( Truong et al . , 2004 , wild - type PRRSV strain , FL12 , was included into this study 
Virology , 325 : 308-19 ) . Four DNA fragments , designated 15 for comparison purposes . The results are shown in FIG . 3 . 
A - D , encompassing the entire PRRSV - CON genome , were After infection , both of the PRRSV - CON and FL12 - inocu 
chemically synthesized by Genscript ( Piscataway , N.J. ) . lated groups displayed significantly higher temperature than 
Each DNA fragment was flanked by a pair of restriction PBS - group ( FIG . 3A ) , but there was no difference in tem 
enzyme sites to facilitate the cloning purposes . The 17 RNA perature between PRRSV - CON - inoculated group and the 
polymerase promoter sequence was incorporated into frag- 20 FL12 - inoculated group . Average daily weight gain ( ADWG ) was measured for each individual pig during the period of 14 ment D , preceding the viral 5'end , to facilitate the in vitro days after infection . No statistical difference was observed transcription of the viral genome . See FIG . 2A . Individual among the three treatment groups , although pigs in the DNA fragments were sequentially cloned into the shuttle PRRSV - CON - inoculated group and the FL12 - inoculated 
vector that carries the corresponding restriction enzyme site , group tended to have lower ADWG than the PBS group 
following the order from fragment A to fragment D. Once 25 ( FIG . 3B ) . Viremia levels of the PRRSV - CON- and FL12 
the full - length PRRSV - CON cDNA clone was generated , inoculated groups were almost identical ( FIG . 3C ) . All pigs 
standard reverse genetics techniques were applied to recover in the PRRSV - CON- and FL12 - inoculated groups were 
viable PRRSV - CON viruses . seroconverted by 11 days p.i. The level of antibody response 
Briefly , the plasmid containing full - length cDNA genome in the PRRSV - CON - inoculated group was slightly lower 
of PRRSV - CON was digested with Acll for linearization . 30 than that of the FL12 - inoculated group ( FIG . 3D ) . These 
The purified , linear DNA fragment was used as the template results demonstrate that the PRRSV - CON can infect the 
for an in vitro transcription reaction using the mMES natural host ( i.e. , pigs ) as efficiently as the PRRSV strain , FL12 . SAGEMMACHINE Ultra T7 kit ( Ambion , Austin , Tex . ) to 
generate full genome viral RNA transcripts . After that , about Example 5 — Evaluation of the Level of 5 ug of the full - genome RNA transcripts were transfected 35 Cross - Protection Against PRRSV Strain MN - 184 into MARC - 145 cells cultured in a 6 - well plate , using the 
TransIT® - mRNA Transfection Kit ( Mirus Bio , Madison , Materials and Methods 
Wis . ) . Transfected cells were cultured in DMEM containing A total of 18 PRRSV - seronegative , 3 week - old pigs were 10 % FBS at 37 ° C. , 5 % CO2 for up to 6 days . Typically , purchased from the University of Nebraska research farm . cytopathic effect ( CPE ) was observed between day 4 and day 40 The pigs were randomly assigned into 3 experimental 
6 after transfection . When clear CPE was observed , culture groups ; each group was housed in a separate room in the 
supernatant containing the rescued virus was collected and Biosecurity Level - 2 Animal Research Facilities at UNL , 
stored in 0.5 mL aliquots in a 80º C. freezer . See , Truong et following the regulations established by the Institutional 
al . ( 2004 , supra ) Animal Care and Use Committee . Group 1 was injected with 
45 PBS and served as the non - immunization control . Group 2 
Example 3 — In Vitro Characterization of the was immunized by infection , intramuscularly , with PRRSV 
PRRSV - CON Virus CON at the dose of 104.0 TCID50 per pig . Group 3 was 
immunized by infection , intramuscularly , with the wild - type 
To study the reactivity with different PRRSV - specific PRRSV strain , FL12 , at the dose of 104.0 TCID50 per pig . 
monoclonal antibodies , MARC - 145 cells were mock 50 See Table 1. At 53 days post - infection ( p.i. ) , all control and 
infected or infected with the PRRSV - CON virus or the immunized pigs were challenged , intramuscularly , with 
PRRSV strain FL12 . At 48 hours post - infection ( p.i. ) , the PRRSV strain MN - 184 at a dose of 105.0 TCID 50. Param 
cells were immunostained with antibodies specific to the eters used to evaluate protection by immunization with the PRRSV - CON virus included viremia and viral load in sev viral nucleocapsid ( N ) protein or the viral nonstructural eral different tissues as well as growth performance . protein 1 beta ( nsplb ) . To study the growth kinetics of the 55 
viruses in cell culture , MARC - 145 cells were infected with TABLE 1 the PRRSV - CON or FL12 at a multiplicity of infection 
( MOI ) of 0.01 . At different time - points p.i. , culture super Experimental Design to Evaluate Level of Cross 
natant was collected and viral titers were determined by Protection Against PRRSV Strain MN - 184 
titration in MARC - 145 cells . Groups Immunized with Challenged with The PRRSV - CON virus displays typical in vitro charac 
terizations of a naturally occurring PRRSV strain . It reacts 1 ( n = 6 ) 
with different PRRSV - specific monoclonal antibodies 2 ( n = 6 ) ( Sub - group 2 ) 
including antibodies against nspl - betta and N protein ( FIG . 
2B ) . It replicates efficiently in cell culture ( FIG . 2C ) , and it 65 
is able to form clear and distinct plaque morphology ( FIG . To measure growth performance , each pig was weighed 
3D ) . right before challenge infection and 15 days post - challenge . 
60 
MN - 184 PBS 
PRRSV - CON 
PRRSV strain FL12 3 n = 
10 
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Body weight was recorded in pounds . Average daily weight purposes , samples that had undetected viral RNA level were 
gain ( ADWG ) was calculated for the period of 15 days assigned a value of 0 log RNA copy / 1 ug of total RNA . 
post - challenge . Results 
To quantitate levels of viremia after challenge infection , The results of growth performance are presented in FIG . 
blood samples were taken before challenge and at days 1 , 4 , 5 4A . The mean ADWG of PBS- , PRRSV - CON- and FL12 immunized groups were 0.3 lbs ( SD +/- 0.3 ) , 0.9 lbs ( SD +/ 7 , 10 , and 15 post - challenge . Serum samples were extracted 0.6 ) , and 1.2 lbs ( SD +/- 0.4 ) , respectively . PRRSV - CON and from each individual blood samples and stored in a -80 ° C. FL12 - immunized groups had greater ADWG than the PBS freezer . Viremia levels were quantitated by the Animal immunized group . There was no statistical difference 
Disease Research and Diagnostic Laboratory , South Dakota between the PRRSV - CON- and FL12 - immunized groups . 
State University , using the universal RT - qPCR kit ( Tetracore The viremia levels after challenge infection are shown in 
Inc. , Rockville , Md . ) . Results were reported as log 10 FIG . 4B and Table 2. All pigs in the PBS - immunized group 
copy / mL . For statistical purposes , samples that had unde were viremic at all timepoints tested . The PRRSV - CON 
tected level of viral RNA were assigned a value of 0 log 10 immunized group only had 3 viremic pigs , of which 1 pig 
copy / mL . was viremic at 2 timepoints ( pig # 494 at 4 DPC and 7 DPC ) 
To quantitate levels of viral load in tissues , pigs were 15 and 2 pigs were viremic at only one timepoint ( pigs # 394 and 495 at 15 DPC ) . The remaining 3 pigs in this group ( pigs humanely sacrificed and necropsied on day 15 post - chal # 345 , 410 and 459 ) were not viremic after challenge infec lenge . Samples of tonsil , lung , mediastinal lymph node and tion . By contrast , viremia was detected in 5 out of 6 pigs in 
inguinal lymph node were obtained and kept individually in the FL12 - immunized group at two time - points or more after 
Whirl - Pak® bags . The samples were snap - frozen in liquid 20 challenge infection . There was only 1 pig in this group ( pig 
nitrogen right after collection . After that , they were stored in # 440 ) that was not viremic at any time - point tested . Overall , 
a -80 ° C. freezer . To extract RNA , tissue samples were the viremia level of PRRSV - CON - immunized pigs was 
homogenized in Trizol reagent ( Life Technologies , Carls significantly lower than that in the FL12 - immunized group 
bad , Calif . ) with a ratio of 300 mg tissue in 3 mL Trizol ( p < 0.05 ) and the PBS - immunized group ( p < 0.0001 ) . 
reagent . Total RNA was extracted using the RNeasy Mini 25 The results of total viral RNA quanititated by the univer 
Kit ( Qiagen , Valencia , Calif . ) following the manufacturer's sal RT - qPCR kit are shown in FIG . 4C . The PRRSV - CON 
instruction . RNA concentration was quantitated by the and FL12 - immunized groups contained significantly lower 
NanoDrop ND - 1000 ( NanoDrop Technologies , Inc. , levels of total viral RNA than the PBS - immunized group , 
Wilmington , Del . ) and adjusted to a final concentration of regardless of the tissue types tested . However , there was no 
200 ng / 4 . 30 difference between the PRRSV - CON- and FL12 - immunized 
It has been well characterized that PRRSV can colonize groups in term of total viral RNA . 
and persist in lymphoid tissues of infected pigs up to 150 The results of MN - 184 specific RNA quantitated by the 
days post - infection . In these experiments , the tissue viral differential RT - qPCR are shown in FIG . 4D . All pigs in 
load was evaluated at 15 days post - challenge , which corre PBS - immunized group carried MN - 184 RNA in their tis 
sponds to 67 days after the primary infection . At that time , 35 sues . Four pigs in the FL 12 - immunized group had MN - 184 
it is likely that the pigs in the PRRSV - CON and FL12 groups RNA in their tonsil and mediastinal lymph node , whereas 5 
still contained residual virus of the primary infection . There pigs in this group had MN - 184 RNA in their inguinal lymph 
fore , we used two different RT - PCR kits to quantify the viral node . Remarkably , none of the pigs in the PRRSV - CON 
RNA load in tissues : ( i ) the commercial RT - qPCR kit immunized group had detectable level of MN - 184 RNA in 
( Tetracore Inc. , Rockville , Md . ) that detects total viral RNA 40 any of the tissue samples tested . 
resulting from both the primary infection and the challenge Taken together , these results clearly demonstrate that 
infection , and ( ii ) the differential RT - PCR developed in immunization of weaning pigs by infection with the non 
house that selectively detects only viral RNA from challenge naturally occurring PRRSV - CON resulted in significantly 
infection . Five uL of each RNA sample ( equivalent to 1 ug better cross - protection against challenge with PRRSV strain , 
RNA ) was used for each RT - PCR reaction . Results were 45 MN - 184 , than did immunization with the PRRSV strain , 
reported as log 10 copy / ug of total RNA . For statistical FL12 . 
TABLE 2 
Viremia After Challenge Infection ( log10 copy / mL ) 
Day post - challenge infection ( DPC ) 
Treatment Pig ID O DPC 1 DPC 4 DPC 7 DPC 10 DPC 15 DPC 
365 0.00 4.94 5.43 5.45 6.79 6.32 
389 0.00 6.26 6.08 5.40 7.60 6.93 
Group 1 
( Injected 
( " immunized ” ) 
with PBS ) 
407 0.00 4.91 6.00 5.86 7.56 6.75 
416 0.00 6.20 6.04 5.20 7.18 6.78 
417 0.00 5.18 5.59 4.86 5.90 6.45 
435 0.00 5.83 5.08 5.94 5.57 5.36 
Mean 0.00 5.55 5.70 5.45 6.77 6.43 
SD 0.00 0.62 0.40 0.40 0.86 0.57 
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TABLE 2 - continued 
Viremia After Challenge Infection ( log10 copy / mL ) 
Day post - challenge infection ( DPC ) 
Treatment Pig ID O DPC 1 DPC 4 DPC 7 DPC 10 DPC 15 DPC 
Group 2 
( Immunized by 
infection with 






















































































































Example 6 — Evaluation of the Level of nized group and the FL12 - immunized group ; whereas the 
Cross - Protection Against PRRSV Strain 16244B FL12 - immunized group was not statistically different from 
25 the PBS - immunized group . 
Materials and Methods The results of viremia levels after challenge infection are 
The experimental design was the same as described above shown in FIG . 5B and Table 4. All pigs in the PBS 
in Example 5. A total of 18 PRRSV - seronegative , 3 week immunized group were viremic at all timepoints tested . Two 
old pigs purchased from the UNL research farm were out of 5 pigs in the PRRSV - CON - immunized group ( pigs 
randomly assigned into 3 experimental groups . Each group # 442 and 445 ) did not resolve viremia at 52 days after 
was housed in separate room at the Biosecurity Level - 2 primary infection as viral RNA was still detected in their 
Animal Research Facilities at UNL , following the regula serum samples collected at this timepoint . After challenge 
tions established by the Institutional Animal Care and Use infection , 3 pigs in the PRRSV - CON - immunized group were Committee . Group 1 was injected with PBS and acted as the 35 viremic at only 1 timepoint . The remaining 2 pigs in this 
control . Group 2 was immunized , intramuscularly , by infec group ( pigs # 436 and 438 ) were not viremic throughout the 
tion with PRRSV - CON at the dose of 104.0 TCID50 per pig . period of 15 days post - challenge . By contrast , all pigs in the 
Group 3 was immunized , intramuscularly , by infection with FL12 - immunized group resolved viremia by 52 days post 
the wild type PRRSV , FL12 , at the dose of 104.0 TCID 50 per primary infection . After challenge infection , all pigs in this 
pig . See Table 3. One pig in group 3 ( pig # 543 ) and one pig 40 group became viremic . Overall , the viremia level of the 
in 2 ( pig # 435 ) were removed from this study on 14 PRRSV - CON - immunized group was significantly lower group 
and 23 days after primary infection , respectively , due to than that of the FL12 - immunized group ( p < 0.0001 ) or the 
lameness in their legs . At day 52 post - infection ( p.i. ) , all pigs PBS - immunized group ( p < 0.0001 ) . 
were challenged , intramuscularly , with PRRSV strain The results of total viral RNA quantitated by the com 
16244B at the challenge dose of 105.0 TCID50 . Parameters mercial RT - qPCR kit ( Tetracore Inc. , Rockville , Md . ) are 
used to evaluate protection by immunization with the shown in FIG . 5C . Both the PRRSV - CON- and FL12 
PRRSV - CON virus , including viremia and viral load in immunized groups contained significantly lower levels of 
various tissues as well as growth performance , were mea total viral RNA than the PBS - immunized group , regardless 
sured as described above in Example 5 . of the tissue types tested . However , there was no statistical 
difference between the PRRSV - CON - immunized group and 
TABLE 3 the FL12 - immunized group in terms of total viral RNA . 
The results of 16244B - specific RNA quantitated by the 
Experimental Design to Evaluate Level of Cross differential RT - qPCR are shown in FIG . 5D . All pigs in the Protection Against PRRSV Strain 16244B PBS- and FL12 - immunized groups carried 16244B - specific 
Groups Challenged with RNA in their tissues , although the levels of 16244B RNA in 
the FL12 - immunized group was lower than those in the 6 ) PBS - immunized group . By contrast , only 1 pig in the 6 ) ( sub - group 3 ) 
3 ( n = 6 ) PRRSV - CON - immunized group carried 16244B - specific 
RNA in its inguinal lymph node , while the remaining 4 pigs 
in this group did not carry 16244B - specific RNA . 
Results All together , these results clearly demonstrate that immu 
The results of growth performance are shown in FIG . 5A . nization of weaning pigs by infection with the non - naturally 
Mean ADWG of PBS- , PRRSV - CON- , and FL12 - immu occurring PRRSV - CON resulted in significantly better 
nized groups were 1.1 lbs ( SD +/- 0.3 ) , 1.6 lbs ( SD +/- 0.1 ) , 65 cross - protection against challenge with PRRSV strain , 
and 0.8 lbs ( SD +/- 0.3 ) , respectively . The PRRSV - CON 16244B , than did immunization with the PRRSV strain , 





= 16244B 1 ( n 
2 ( n 
PBS 
PRRSV - CON 
PRRSV strain FL12 
60 
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TABLE 4 
Level of Viremia After Challenge Infection ( log10 copy / mL ) 
Day post - challenge 
Treatment Pig ID O DPC 1 DPC 4 DPC 7 DPC 11 DPC 14 DPC 
Group 1 
( Injected 




























0.00 6.62 6.99 6.79 6.15 4.67 
0.00 6.61 6.93 7.11 5.79 4.81 
0.00 6.85 6.82 6.96 3.91 5.68 
0.00 7.11 7.41 7.11 6.81 5.93 
0.00 6.74 7.45 7.30 5.67 5.40 
0.00 6.77 7.51 7.36 6.73 5.52 
0.00 6.78 7.18 7.11 5.84 5.34 
0.00 0.18 0.30 0.21 1.06 0.50 
Removed from experiment on day 23rd after primary 
infection 
0.00 0.00 0.00 0.00 0.00 0.00 
0.00 2.48 0.00 0.00 0.00 0.00 
0.00 0.00 0.00 0.00 0.00 0.00 
2.81 0.00 0.00 0.00 0.00 2.93 
3.00 3.32 0.00 0.00 0.00 0.00 
1.16 1.16 0.00 0.00 0.00 0.59 
1.59 1.62 0.00 0.00 0.00 1.31 
0.00 4.34 6.78 3.54 2.48 0.00 
0.00 3.04 6.58 0.00 0.00 0.00 
0.00 5.26 4.84 0.00 0.00 0.00 
0.00 2.98 4.40 4.15 0.00 0.00 
0.00 3.90 4.18 5.08 3.95 0.00 
Removed from experiment on day 14th after primary 
infection 
0.00 3.90 5.35 2.55 1.29 0.00 








It is to be understood that , while the methods and com 
positions of matter have been described herein in conjunc 
tion with a number of different aspects , the foregoing 
description of the various aspects is intended to illustrate and 
not limit the scope of the methods and compositions of 
matter . Other aspects , advantages , and modifications are 
within the scope of the following claims . 
Disclosed are methods and compositions that can be used 
for , can be used in conjunction with , can be used in prepa 
ration for , or are products of the disclosed methods and 
compositions . These and other materials are disclosed 
herein , and it is understood that combinations , subsets , 
interactions , groups , etc. of these methods and compositions 
are disclosed . That is , while specific reference to each 
various individual and collective combinations and permu 
tations of these compositions and methods may not be 
explicitly disclosed , each is specifically contemplated and 
35 described herein . For example , if a particular composition of 
matter or a particular method is disclosed and discussed and 
a number of compositions or methods are discussed , each 
and every combination and permutation of the compositions 
and the methods are specifically contemplated unless spe 
cifically indicated to the contrary . Likewise , any subset or 




< 160 > NUMBER OF SEQ ID NOS : 43 
< 210 > SEQ ID NO 1 
< 211 > LENGTH : 15456 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 1 
atgacgtata ggtgttggct ctatgccatg acatttgtat tgtcaggagc tgcgaccatt 60 
ggtacagccc aaaactagct gcacagaaaa cgcccttctg tgacagccct cttcagggga 120 
gcttaggggt ctgtccctag caccttgctt ccggagttgc actgctttac ggtctctcca 180 
accctttaac catgtctggg atacttgatc ggtgcacgtg tacccccaat gccagggtgt 240 
ttatggcgga gggccaagtc tactgcacac gatgtctcag tgcacggtct ctccttcctc 300 
tgaatctcca agttcctgag ct ggggtgc tgggcctatt ttacaggccc gaagagccac 360 
tccggtggac gttgccacgt gcattcccca ctgtcgagtg ctcccccgcc ggggcctgct 420 
ggctttctgc gatctttcca attgcacgaa tgaccagtgg aaacctgaac tttcaacaaa 480 
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gaatggtgcg ggtcgcagct gagctttaca gagccggcca gctcacccct gcagtcttga 540 
aggctctaca agtttatgaa cggggttgcc gctggtaccc cattgttgga cctgtccctg 600 
gagtggccgt tttcgccaac tccctacatg tgagtgataa acctttcccg ggagcaactc 660 
atgtgttaac caacctgccg ctcccgcaga ggcccaagcc tgaagacttt tgcccctttg 720 
agtgtgctat ggctgacgtc tatgacattg gtcatgacgc cgtcatgtat gtggccgaag 780 
ggaaagtctc ctgggcccct cgtggcgggg atgaagggaa atttgaaact gtccccgagg 840 
agttgaagtt gattgcgaac cgactccaca tctccttccc gccccaccac gcagtggaca 900 
tgtctaagtt tgccttcata gcccctggga gtggtgtttc catgcgggtc gagtgccaac 960 
acggctgcct ccccgctgac actgtccctg aaggcaactg ctggtggcgc ttgtttgact 1020 
tgctcccact ggaagttcag aacaaagaaa ttcgccatgc taaccaattt ggctatcaga 1080 
ccaagcatgg tgtcgctggc aagtacctac agcggaggct gcaagttaat ggtctccgag 1140 
cagtgactga cccaaatgga cctatcgtcg tacagtattt ctctgttaag gagagctgga 1200 
tccgccactt aagactggcg gaagaaccta gcctccctgg gtttgaggac ctcctcagaa 1260 
taagggttga gcccaacacg tcgccattgg ctgacaagga tgagaaaatc ttccggtttg 1320 
gcagtcacaa gtggtacggt gctggaaaga gggcaaggaa agcacgctct ggtgcgactg 1380 
ccacagtcgc tcaccgcgct ttgcccgctc gtgaaaccca gcaggccaag aagcacgagg 1440 
ttgccagcgc caacaaggct gagcatctca agcactattc cccgcctgcc gacgggaact 1500 
gtggttggca ctgcatttcc gccatcgcca accggatggt gaattccaaa tttgaaacca 1560 
cccttcccga aagagtgaga ccttcagatg actgggctac tgacgaggat cttgtgaata 1620 
ccatccaaat cctcaggctc cctgcggcct tggacaggaa cggtgcttgt gotagcgcca 1680 
agtacgtgct taagctggaa ggtgagcatt ggactgtctc tgtgacccct gggatgtccc 1740 
cttctttgct cccccttgaa tgtgttcagg gctgttgtga gcataagggc ggtcttggtt 1800 
ccccagatgc ggtcgaagtt tccggatttg accctgcctg ccttgaccga ctggctgagg 1860 
tgatgcactt gcctagcagt gccatcccag ccgctctggc cgaaatgtcc ggcgacccca 1920 
atcgtccggc ttccccggtc accactgtgt ggactgtttc gcagttcttt gcccgtcaca 1980 
gaggaggaga gcaccctgat caggtgtgct tagggaaaat catcagcctt tgtcaggtga 2040 
ttgaggaatg ctgctgttcc cagaacaaaa ccaaccgggt caccccggaa gaggtcgcgg 2100 
caaagattga ccagtacctc cgtggtgcaa caagtcttga agaatgottg gccaggcttg 2160 
agagggctcg cocgccgagc gcaatggaca cctcctttga ttggaatgtt gtgctccctg 2220 
gggttgaggc ggcaactcag acaaccaaac agccccatgt caaccagtgc cgcgctctgg 2280 
tccctgtcgt gactcaagag tctttggaca aagactcggt ccctctgacc gccttctcgc 2340 
tgtctaattg ctactaccct gcacaaggtg acgaggttcg tcaccgtgag aggctaaact 2400 
ccgtgctctc taagttggag gaggttgttc gtgaggaata tgggctcacg ccaactggac 2460 
ctggcccgcg acccgcactg ccgaacgggc tcgacgaact taaagaccag atggaggagg 2520 
atctgctgaa actagtcaac gcccaggcaa cttcagaaat gatggcctgg gcagccgagc 2580 
aggttgatct aaaagcttgg gtcaaaaact acccacggtg gacaccgcca ccccctccac 2640 
caagagttca gcctcgaaaa acgaagtctg tcaagagctt gccagagaac aagcctgtcc 2700 
ctgctccgcg caggaaggtc agatctgatt gtggcagccc gattttaatg ggcgacaatg 2760 
tccctaacag ttgggaagat ttggctgttg gtggccccct tgatctctcg acaccacccg 2820 
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agccgatgac acctctgagt gagcctgcac ttatgcccgc gttgcaacat atttctaggo 2880 
cagtgacacc tttgagtgtg ccggccccaa ttcctgcacc gcgcagagct gtgtcccgac 2940 
cggtgacgcc ctcgagtgag ccaatttctg tgtctgcacc gcgacataaa tttcagcagg 3000 
tggaagaagc gaatctggcg gcagcaacgc tgacgtacca ggacgaaccc ctagatttgt 3060 
ctgcatcctc acagactgaa tatgaggctt ctcccctagc accactgcag aacatgggta 3120 
ttctggaggt gggggggcaa gaagctgagg aaattctgag tgaaatctcg gacataccga 3180 
atgacatcaa ccctgcgcct gtgtcatcaa gcagctccct gtcaagcgtt aagatcacac 3240 
gcccaaaata ctcagctcaa gccatcatcg actcgggcgg gccctgcagt gggcatctcc 3300 
aaaaggaaaa agaagcatgo ctcagcatca tgcgtgaggc ttgtgatgcg actaagcttg 3360 
gtgaccctgc cacgcaggaa tggctttctc gcatgtggga tagggtggac atgctgactt 3420 
ggcgcaacac gtctgcttac caggcgtttc gcaccttaga tggcaggttt gagtttctcc 3480 
caaagatgat actcgagaca ccgccgccct acccgtgtgg gtttgtgatg ctgcctcaca 3540 
cgcctgcacc ttccgtgggt gcggagagcg accttaccat tggttcagtc gocactgaag 3600 
atgttccacg catcctcggg aaaatagaaa atgccggcga gatgaccaac cagggaccct 3660 
tggcatcctc cgaggaagaa ccggcagacg accaacctgc caaagactcc cggatatcgt 3720 
cgcgggggtt tgacgagagc acagcagctc cgtccgcagg cacaggtggc gccggcttat 3780 
ttactgattt gccaccttca gacggtgtag atgcggacgggggggggccg ttacagacgg 3840 
taaaaaagaa agctgaaagg ctcttcgacc aattgagccg tcaggttttt aacctcgtct 3900 
cccatctccc tgttttcttc tcacacctct tcaaatctga cagtggttat tctccgggtg 3960 
attggggttt tgcagctttt actctatttt gcctcttttt atgttacagt tacccattct 4020 
ttggttttgc tcccctcttg ggtgtgtttt ctgggtcttc tcggcgcgtg cgcatggggg 4080 
tttttggctg ctggttggct tttgctgttg gtctgttcaa gcctgtgtcc gacccagtcg 4140 
gcactgcttg tgagtttgat tcgccagagt gtaggaacgt ccttcattct tttgagcttc 4200 
tcaaaccttg ggaccctgtt cgcagccttg ttgtgggccc cgtcggtctc ggtcttgcca 4260 
ttcttggcag gttactgggc ggggcacgct acatctggca ttttttgctt aggettggca 4320 
ttgttgcaga ctgtatcttg gctggagctt atgtgctttc tcaaggtagg tgtaaaaagt 4380 
gctggggatc ttgtataaga actgctccta atgagatcgc ctttaacgtg ttccctttta 4440 
cacgtgcgac caggtcgtca ctcatcgacc tgtgcgatcg gttttgtgcg ccaaaaggca 4500 
tggaccccat tttcctcgcc actgggtggc gcgggtgctg gaccggccga agccccattg 4560 
agcaaccctc tgaaaaaccc atcgcgtttg cccagttgga tgaaaagaag attacggcta 4620 
ggactgtggt cgcccagcct tatgacccca accaagccgt aaagtgcttg cgggtgttac 4680 
aggcgggtgg ggcgatggtg gctgaggcag tcccaaaagt ggtcaaggtt tccgctatto 4740 
cattccgagc cccctttttt cccaccggag tgaaagttga ccctgagtgc aggatcgtgg 4800 
ttgaccccga cactttcact acagctctcc ggtctggcta ctccaccaca aacctcgtcc 4860 
ttggtgtggg ggactttgcc cagctgaatg gattaaaaat caggcaaatt tccaagcctt 4920 
caggaggagg cccacacctc attgctgccc tgcatgttgc ctgctcgatg gcgttgcaca 4980 
tgottgctgg gatttatgta actgcagtggggtcttgcgg taccggcacc aacgatccgt 5040 
ggtgcactaacccgt gec gtccctggct acg gg ctctctctgc acgtccagat 5100 
tgtgcatctc ccaacatggc cttaccctgc ccttgacagc acttgtggca ggattcggtc 5160 
ttcaggaaat tgccttggtt gttttgattt tcgtttccat cggaggcatg gctcacaggt 5220 
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tgagttgcaa ggctgatatg ctgtgcgttt tacttgcaat cgccagctat gtttgggtac 5280 
cccttacctg gttgctttgt gtgtttcctt gctggttgcg ctggttctct ttgcaccccc 5340 
tcaccatcct atggttggtg tttttcttga tttctgtaaa tatgccttca ggaatcttgg 5400 
ccgtggtgtt gttggtttct ctttggcttc taggtcgtta tactaatgtt gctggtcttg 5460 
tcacccccta tgacattcat cattacacca gtggcccccg cggtgttgcc gccttggcta 5520 
ccgcaccaga tgggacctac ttggccgctg tccgccgcgc tgcgttgact ggccgcacca 5580 
tgctgtttac cccgtctcag cttgggtccc ttcttgaggg tgctttcaga actcaaaagc 5640 
cctcactgaa caccgtcaat gtggtcgggt cctccatggg ctctggcggg gtgttcacca 5700 
tcgacgggaa aattaagtgc gtaactgccg cacatgtcct tacgggtaat tcagctaggg 5760 
tttccggggt cggcttcaat caaatgcttg actttgatgt aaaaggggac ttcgccatag 5820 
ctgattgccc gaattggcaa ggggctgctc ccaagaccca attctgcaag gatggatgga 5880 
ctggccgtgc ctattggctg acatcctctg gcgtcgaacc cggtgtcatt gggaatggat 5940 
tcgccttctg cttcaccgcg tgcggcgatt ccgggtcccc agtgatcacc gaagccggtg 6000 
agcttgtcgg cgttcacaca ggatcaaaca aacaaggagg aggcattgtc acgcgcccct 6060 
caggccagtt ttgtaatgtg gcacccatca agctgagcga attaagtgaa ttctttgctg 6120 
gacctaaggt cccgctcggt gatgtgaagg ttggcagcca cataattaaa gacataagcg 6180 
aggtgccttc agatctttgc gccttgottg ctgccaaacc cgaactggaa ggaggcctct 6240 
ccaccgtcca acttctgtgt gtgtttttcc tcctgtggag aatgatggga catgcctgga 6300 
cgcccttggt tgctgtgggt ttttttatct tgaatgaggt tctcccagct gtcctggtcc 6360 
ggagtgtttt ctcctttgga atgtttgtgc tatcttggct cacaccatgg tctgcgcaag 6420 
ttctgatgat caggcttcta acagcagctc ttaacaggaa cagatggtca cttgcctttt 6480 
acagcctcgg tgcagtgacc ggttttgtcg cagatcttgc ggcaactcag gggcatccgt 6540 
tgcaggcagt gatgaattta agcacctatg ccttcctgcc tcggatgatg gttgtgacct 6600 
caccagtccc agtgattgcg tgtggtgttg tgcacctcct toccataatt ttgtacttgt 6660 
ttaagtaccg ttgcctgcac aatgtccttg ttggcgatgg agtgttctct gcggctttct 6720 
tcttgcgata ctttgccgag ggaaagttga gggaaggggt gtcgcaatcc tgcgggatga 6780 
atcatgagtc actgactggt gccctcgcta tgagactcaa tgacgaggac ttggatttcc 6840 
ttacgaaatg gactgatttt aagtgctttg tttctgcgtc caacatgagg aatgcagcgg 6900 
gccaattcat cgaggctgcc tatgctaaag cacttagagt agaacttgcc cagttggtgc 6960 
aggttgataa ggttcgaggt actttggcca aacttgaagc ttttgctgat accgtggcac 7020 
cccaactctc gcccggtgac attgttgttg ctcttggcca cacgcctgtt ggcagtatct 7080 
tcgacctaaa ggttggtagc accaagcata ccctccaagc cattgagacc agagtccttg 7140 
ccgggtccaa aatgaccgtg gcgcgcgtcg ttgacccaac ccccacgcccccacccgcac 7200 
ccgtgcccat ccccctccca ccgaaagttc tggagaatgg ccccaacgcc tggggggatg 7260 
aggaccgttt gaataagaag aagaggcgca ggatggaagc cgtcggcatc tttgttatgg 7320 
gcgggaagaa gtaccagaaa ttttgggaca agaattccgg tgatgtgttt tatgaggagg 7380 
tccatgataa cacagatgcg tgggagtgcc tcagagttgg cgaccctgcc gactttgacc 7440 
ctgagaaggg aactctgtgt gggcatacca ccattgaaga taaggettac aatgtctacg 7500 
cctccccatc tggcaagaag ttcctggtcc ccgtcaaccc agagagcgga agagcccaat 7560 
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gggaagctgc aaagctttcc gtggagcagg cccttggcat gatgaatgtc gacggtgaac 7620 
tgacagccaa agaactggag aaactgaaaa gaataattga caaactccag ggcctgacta 7680 
aggagcagtg tttaaactgc tagccgccag cggcttgacc cgctgtggtc gcggcggett 7740 
ggttgttact gagacagcgg taaaaatagt caaatttcac aaccggacct tcaccctagg 7800 
acctgtgaat ttaaaagtgg ccagtgaggt tgagctaaaa gacgcggtcg agcacaacca 7860 
acacccggtt gcaagaccgg ttgatggtgg tgttgtgctc ctgcgctccg cagttccttc 7920 
gottatagac gtcttgatct ccggtgctga tgcatctccc aagttactcg cccgccacgg 7980 
gccgggaaac actgggatcg atggcacgct ttgggatttt gaggccgaag ccaccaaaga 8040 
ggaaatcgca ctcagtgcgc aaataataca ggcttgtgac attaggcgcg gegacgcacc 8100 
tgaaattggt ctcccttaca agctgtaccc tgttaggggc aaccctgagc gggtaaaagg 8160 
agttttgcag aatacaaggt ttggagacat accttacaaa acccccagtg acactggaag 8220 
cccagtgcac gcggctgcct gcctcacgcc caatgccact ccggtgactg atgggcgctc 8280 
cgtcttggcc acgaccatgc cctccggttt tgagttgtat gtaccgacca ttccagcgtc 8340 
tgtccttgat tatcttgatt ctaggcctga ctgccccaaa cagttgacag agcacggctg 8400 
tgaggatgcc gcattgagag acctctccaa gtatgacttg tccacccaag gctttgtttt 8460 
gcctggagtt cttcgccttg tgcgtaagta cctgtttgcc catgtgggta agtgcccgcc 8520 
cgttcatcgg ccttccactt accctgccaa gaattctatg gctggaataa atgggaacag 8580 
gtttccaacc aaggacattc agagcgtccc tgaaatcgac gttctgtgcg cacaggccgt 8640 
gcgagaaaac tggcaaactg ttaccccttg taccctcaag aaacagtatt gcgggaagaa 8700 
gaagactagg acaatactcg gcaccaataa cttcattgcg ctggcccacc gggcagcgtt 8760 
gagtggtgtc acccagggct tcatgaaaaa ggcgtttaac tcgcccatcg ccctcgggaa 8820 
aaacaaattt aaggagctac agactccggt cttgggcagg tgccttgaag ctgatcttgc 8880 
atcctgcgat cgatccacac ctgcaattgt ccgctggttt gccgccaatc ttctttatga 8940 
acttgcctgt gotgaagagc atctaccgtc gtacgtgctg aactgctgcc acgacttact 9000 
ggtcacgcag tocggcgcag tgactaagag aggtggcctg tcgtctggcg acccgatcac 9060 
ttctgtgtcc aacaccattt acagcttggt gatatatgca cagcacatgg tgctcagtta 9120 
ctttaaaagt ggtcaccccc atggccttct gtttctacaa gaccagctaa agtttgagga 9180 
catgctcaag gttcaacccc tgatcgtcta ttcggacgac ctcgtgctgt atgccgagtc 9240 
tcccaccatg ccaaactacc actggtgggt tgaacatctg aacctgatgc tgggttttca 9300 
gacggaccca aagaagacag ccataacaga ctcgccatca tttctaggct gtaggataat 9360 
aaatgggcgc cagctagtcc ccaaccgtga caggattctc gcggccctcg cctaccacat 9420 
gaaggcgagc aatgtttctg aatactacgc ctcggcggct gcaatactca tggacagctg 9480 
tgottgtttg gagtatgatc ctgaatggtt tgaagaactt gtggttggaa tagcgcagtg 9540 
cgcccgcaag gacggctaca gctttcccgg cccgccgttc ttcttgtcca tgtgggaaaa 9600 
actcaggtcc aattatgagg ggaagaagtc cagagtgtgc gggtactgeg gggccccggc 9660 
cccgtacgcc actgcctgtg gcctcgacgt ctgtatttac cacacccact tccaccagca 9720 
ttgtccagtc ataatctggt gtggccatcc agcgggttct ggttcttgta gtgagtgcaa 9780 
acccccccta gggaaaggca caagccctct agat ttg caag toccgtataa 9840 
gcctccacgg accgtaatca tgcatgtgga gcagggtctc acccctcttg acccaggcag 9900 
ataccagact cgccgcggat tagtctccgt taggcgtggc atcaggggaa atgaagttga 9960 
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cctaccagac ggtgattatg ctagcaccgc cttgctcccc acttgtaaag agatcaacat 10020 
ggtcgctgtc gcttctaatg tgttgcgcag caggttcatc atcggtccac ccggtgctgg 10080 
gaaaacatac tggctccttc aacaggtcca ggatggtgat gtcatttaca caccaactca 10140 
tcagaccatg cttgacatga ttaaggettt ggggacgtgc cggttcaacg tcccggcagg 10200 
cacaacgctg caattccctg ccccctcccg taccggcccg tgggttcgca tcctggccgg 10260 
cggttggtgt cctggcaaga attccttcct ggatgaagca gcgtattgta atcaccttga 10320 
tgtcttgagg cttcttagca aaactaccct cacctgtctg ggagacttca aacaactcca 10380 
cccagtgggt tttgattctc attgctatgt ttttgacatc atgcctcaga ctcaactgaa 10440 
gaccatctgg aggtttggac agaatatctg tgatgccatt cagccagatt acagggacaa 10500 
acttgtgtcc atggtcaaca caacccgtgt aacctacgtg gaaaaacctg tcaagtatgg 10560 
gcaagtcctc accccttacc acagggaccg agaggacggc gccatcacaa ttgactccag 10620 
tcaaggcgcc acatttgatg tggttacatt gcatttgccc actaaagatt cactcaacag 10680 
gcaaagagcc cttgttgcta tcaccagggc aagacatgct atctttgtgt atgacccaca 10740 
caggcaactg cagagcatgt ttgatcttcc tgcaaaaggc acacccgtca acctcgccgt 10800 
gcaccgtgac gagcagctga tcgtgctaga tagaaataac aaagaatgca cggttgctca 10860 
ggctctaggc aatggggata aattcagggc cacagacaag cgcgttgtag attctctccg 10920 
cgccatttgt gcagatctag aagggtcgag ctctccgctc cccaaggtcg cacacaactt 10980 
gggattttat ttctcacctg atttgacaca gtttgotaaa ctcccggtag aacttgcacc 11040 
ccactggccc gtggtgacaa cccagaacaa tgaaaagtgg ccagaccggc tggttgccag 11100 
ccttcgccct atccataaat atagccgcgc gtgcatcggt gccggctata tggtgggccc 11160 
ctcggtgttt ctaggcaccc ctggggttgt gtcatactat ctcacaaaat ttgttaaggg 11220 
cgaggctcaa gtgcttccgg agacagtctt cagcaccggc cgaattgagg tagattgccg 11280 
ggagtatott gatgatcggg agcgagaagt tgctgagtcc ctcccacatg ccttcattgg 11340 
cgacgtcaaa ggcactaccg ttggaggatg tcaccatgtc acctccaaat accttccgcg 11400 
cttccttccc aaggaatcag ttgcggtagt cggggtttca agccccggga aagccgcaaa 11460 
agcagtttgc acattaacag atgtgtacct cccagacctt gaagcttacc tccacccaga 11520 
gacccagtcc aagtgctgga aaatgatgtt ggacttcaag gaagttcgac tgatggtctg 11580 
gaaagacaaa acggcctatt ttcaacttga aggccgccat ttcacctggt atcagcttgc 11640 
aagctatgcc tcgtacatcc gagttcctgt taactctacg gtgtatttgg acccctgcat 11700 
gggccctgcc ctttgcaaca gaagagttgt cgggtccact cattgggggg ctgacctcgc 11760 
agtcacccct tatgattatg gtgccaaaat cattctgtct agtgcatacc atggtgaaat 11820 
gcctcctggg tacaaaatcc tggcgtgcgc ggagttctcg cttgacgatc cagtgaggta 11880 
caaacacacc tgggggtttg aatcggatac agcgtatctg tacgagttca ccggaaacgg 11940 
tgaggactgg gaggattaca atgatgcgtt tcgtgcgcgc cagaaaggga aaatttataa 12000 
ggccactgcc accagcatga ggtttcattt tcccccgggc cctgtcattg aaccaacttt 12060 
gggcctgaat tgaaatgaaa tgggggctat gcaaagcctt tttgacaaaa ttggccaact 12120 
ttttgtggat gctttcacgg aatttttggt gtccattgtt gatatcatca tatttttggc 12180 
cattttgttt ggcttcacca tcgccggttg gctggtggtc ttttgcatca gattggtttg 12240 
ctccgcggta ctccgtgcgc gccctaccat tcaccctgag caattacaga agatcctatg 12300 
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aggcctttct ttctcagtgc cgggtggaca ttcccacctg gggaactaaa catcccttgg 12360 
ggatgctttg gcaccataag gtgtcaaccc tgattgatga aatggtgtcg cgtcgaatgt 12420 
accgcatcat ggaaaaagca ggacaggctg cctggaaaca ggtggtgagc gaggctacgc 12480 
tgtctcgcat tagtggtttg gatgtggtgg ctcattttca gcatcttgcc gccattgaag 12540 
ccgagacctg taaatatttg gcctctcggc tgcccatgct acacaacctg cgcatgacag 12600 
ggtcaaatgt aaccatagtg tataatagta ctttgaatca ggtgtttgct atttttccaa 12660 
cccctggttc ccggccaaag cttcatgatt ttcagcaatg gctaatagct gtgcattcct 12720 
ccatattttc ctctgttgca gcttcttgta ctctttttgt tgtgctgtgg ttgcggattc 12780 
caatgctacg tactgttttt ggtttccact ggttaggggc aatttttcct tcgaactcac 12840 
agtgaattac acggtgtgtc caccttgcct cacccggcaa gcagccgctg agatctacga 12900 
acccggcagg tctctttggt gcaggatagg gcatgaccga tgtagggagg acgatcatga 12960 
cgaactaggg ttcatggttc cgcctggcct ctccagcgaa ggccacttga ccagtgttta 13020 
cgcctggttg gcgttcctgt ccttcagcta cacggcccag ttccatcccg agatatttgg 13080 
gatagggaat gtgagtcaag tttatgttga catcaagcac caattcatct gcgccgaaca 13140 
tgacgggcag aacgccacct tgcctcgcca tgacaacatt tcagccgtgt ttcagaccta 13200 
ctaccaacat caggtcgacg goggcaattg gtttcaccta gaatggctgc gccccttctt 13260 
ttcctcttgg ttggttttaa atgtttcgtg gtttctcagg cgttcgcctg caagccatgt 13320 
ttcagttcga gtctttcaga catcaagacc aacaccaccg cagcagcaag ctttgttgtc 13380 
ctccaagaca tcagctgcct taggcatggc gactcgtcct ctgaggcgat tcgcaaaagc 13440 
tctcagtgcc gcacggcgat agggacaccc gtgtacatca ccatcacagc caatgtgaca 13500 
gatgagaatt atttacattc ttctgatctc ctcatgcttt cttcttgcct tttctatgct 13560 
tctgagatga gtgaaaaggg attcaaggtg gtatttggca atgtgtcagg catcgtggct 13620 
gtgtgtgtca actttaccag ctacgtccaa catgtcaagg agtttaccca acgctccttg 13680 
gtggtcgacc atgtgcggct gottcatttc atgacacctg agaccatgag gtgggcaacc 13740 
gttttagcct gtctttttgc cattctgttg gcaatttgaa tgttcaagta tgttggggaa 13800 
atgottgacc gcgggctgtt gotcgcgatt gotttctttg tggtgtatcg tgccgttctg 13860 
ttttgctgcg ctcgtcaacg ccaacagcaa cagcagctcc catttacagt tgatttacaa 13920 
cttgacgcta tgtgagctga atggcacaga ttggctggct aacaaatttg attgggcagt 13980 
ggagactttt gtcatctttc ccgtgttgac tcacattgtc tcctatggtg ccctcaccac 14040 
cagccatttc cttgacacag tcggtctggt cactgtgtct accgccgggt tttatcacgg 14100 
gcggtatgtc ttgagtagca tctacgcggt ctgtgccctg gctgcgttga tttgcttcgt 14160 
cattaggttt gcgaagaact gcatgtcctg gcgctactca tgtaccagat ataccaactt 14220 
tcttctggac actaagggca gactctatcg ttggcggtcg cocgtcatca tagagaaaag 14280 
gggtaaagtt gaggtcgaag gtcatctgat cgacctcaaa agagttgtgc ttgatggttc 14340 
cgtggcaacc cctttaacca gagtttcagc ggaacaatgg ggtcgtcctt agacgacttc 14400 
toccatgata gcacggctcc acaaaaggtg cttttggcgt tttctattac ctacacgcca 14460 
gtgatgatat atgccctaaa ggtaagtcgc ggccgactgc tagggcttct gcaccttttg 14520 
atttttctga att gcttt cacct gg tacatgacat tcgcg actt tcagagcaca 14580 
aataaggtcg cgctcactat gggagcagta gttgcactcc tttggggggt gtactcagcc 14640 
atagaaacct ggaaattcat cacctccaga tgccgtttgt gottgctagg ccgcaagtac 14700 
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attctggccc ctgcccacca cgttgaaagt gccgcaggct ttcatccgat tgcggcaaat 14760 
gataaccacg catttgtcgt ccggcgtccc ggctccacta cggtcaacgg cacattggtg 14820 
cccgggttga aaagcctcgt gttgggtggc agaaaagctg ttaaacaggg agtggtaaac 14880 
cttgtcaaat atgccaaata acaacggcaa gcagcagaag aaaaagaagggggatggcca 14940 
gccagtcaat cagctgtgcc agatgctggg taagatcatc gcccagcaaa accagtccag 15000 
aggcaaggga ccgggaaaga aaaataagaa gaaaaacccg gagaagcccc attttcctct 15060 
agcgactgaa gatgacgtca gacatcactt tacccctagt gagcggcaat tgtgtctgtc 15120 
gtcaatccag actgccttta atcaaggcgc tggaacttgt accctgtcag attcagggag 15180 
gataagttac actgtggagt ttagtttgcc gacgcatcat actgtgcgcc tgatccgcgt 15240 
cacagcatca ccctcagcat gatgggctgg cattccttaa gcacctcagt gttagaattg 15300 
gaagaatgtg tggtgaatgg cactgattgg cactgtgcct ctaagtcacc tattcaatta 15360 
gggcgaccgt gtgggggtta agtttaattg gcgagaacca tgcggccgaa attaaaaaaa 15420 
?????????????????????????????? aaaaaa 15456 
< 210 > SEQ ID NO 2 
< 211 > LENGTH : 540 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 2 
atgtctggga tacttgatcg gtgcacgtgt acccccaatg ccagggtgtt tatggcggag 60 
ggccaagtct actgcacacg atgtctcagt gcacggtctc tccttcctct gaatctccaa 120 
gttcctgagc tcggggtgct gggcctattt tacaggcccg aagagccact ccggtggacg 180 
ttgccacgtg cattccccac tgtcgagtgc tcccccgccg gggcctgctg gotttctgcg 240 
atctttccaa ttgcacgaat gaccagtgga aacctgaact ttcaacaaag aatggtgcgg 300 
gtcgcagctg agctttacag agccggccag ctcacccctg cagtcttgaa ggctctacaa 360 
gtttatgaac ggggttgccg ctggtacccc attgttggac ctgtccctgg agtggccgtt 420 
ttcgccaact ccctacatgt gagtgataaa cctttcccgg gagcaactca tgtgttaacc 480 
aacctgccgc tcccgcagag gcccaagcct gaagactttt gcccctttga gtgtgctatg 540 
< 210 > SEQ ID NO 3 
< 211 > LENGTH : 180 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 3 
Met Ser Gly Ile Leu Asp Arg Cys Thr Cys Thr Pro Asn Ala Arg Val 
1 5 10 15 
Phe Met Ala Glu Gly Gin Val Tyr Cys Thr Arg Cys Leu Ser Ala Arg 
20 25 30 
Ser Leu Leu Pro Leu Asn Leu Gin Val Pro Glu Leu Gly Val Leu Gly 
35 40 45 
Leu Phe Tyr Arg Pro Glu Glu Pro Leu Arg Trp Thr Leu Pro Arg Ala 
60 50 55 
Phe Pro Thr Val Glu Cys Ser Pro Ala Gly Ala Cys Trp Leu Ser Ala 
65 70 75 80 
Ile Phe Pro Ile Ala Arg Met Thr Ser Gly Asn Leu Asn Phe Gln Gln 
85 90 95 
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Arg Met Val Arg Val Ala Ala Glu Leu Tyr Arg Ala Gly Gln Leu Thr 
100 105 110 
Pro Ala Val Leu Lys Ala Leu Gln Val Tyr Glu Arg Gly Cys Arg Trp 
115 120 125 
Tyr Pro Ile Val Gly Pro Val Pro Gly Val Ala Val Phe Ala Asn Ser 
130 135 140 
Leu His Val Ser Asp Lys Pro Phe Pro Gly Ala Thr His Val Leu Thr 
145 150 155 160 
Asn Leu Pro Leu Pro Gln Arg Pro Lys Pro Glu Asp Phe Cys Pro Phe 
165 170 175 
Glu Cys Ala Met 
180 
< 210 > SEQ ID NO 4 
< 211 > LENGTH : 609 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 4 
gctgacgtct atgacattgg tcatgacgccgtcatgtatg tggccgaagg gaaagtctcc 60 
tgggcccctc gtggcgggga tgaagggaaa tttgaaactg tccccgagga gttgaagttg 120 
attgcgaacc gactccacat ctccttcccg ccccaccacg cagtggacat gtctaagttt 180 
gccttcatag cccctgggag tggtgtttcc atgcgggtcg agtgccaaca cggctgcctc 240 
cccgctgaca ctgtccctga aggcaactgc tggtggcgct tgtttgactt gctcccactg 300 
gaagttcaga acaaagaaat tcgccatgct aaccaatttg gctatcagac caagcatggt 360 
gtcgctggca agtacctaca gcggaggctg caagttaatg gtctccgagc agtgactgac 420 
ccaaatggac ctatcgtcgt acagtatttc tctgttaagg agagctggat ccgccactta 480 
agactggcgg aagaacctag cctccctggg tttgaggacc tcctcagaat aagggttgag 540 
cccaacacgt cgccattggc tgacaaggat gagaaaatct tccggtttgg cagtcacaag 600 
tggtacggt 609 
< 210 > SEQ ID NO 5 
< 211 > LENGTH : 203 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 5 
Ala Asp Val Tyr Asp Ile Gly His Asp Ala Val Met Tyr Val Ala Glu 
1 5 10 15 
Gly Lys Val Ser Trp Ala Pro Arg Gly Gly Asp Glu Gly Lys Phe Glu 
20 25 30 
Thr Val Pro Glu Glu Leu Lys Leu Ile Ala Asn Arg Leu His Ile Ser 
35 40 45 
Phe Pro Pro His His Ala Val Asp Met Ser Lys Phe Ala Phe Ile Ala 
50 55 60 
Pro Gly Ser Gly Val Ser Met Arg Val Glu Cys Gin His Gly Cys Leu 
65 70 75 80 
Pro Ala Asp Thr Val Pro Glu Gly Asn Cys Trp Trp Arg Leu Phe Asp 
85 90 95 
Leu Leu Pro Leu Glu Val Gln Asn Lys Glu Ile Arg His Ala Asn Gln 
100 105 110 
Phe Gly Tyr Gln Thr Lys His Gly Val Ala Gly Lys Tyr Leu Gin Arg 
115 120 125 
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Arg Leu Gin Val Asn Gly Leu Arg Ala Val Thr Asp Pro Asn Gly Pro 
130 135 140 
Ile Val Val Gin Tyr Phe Ser Val Lys Glu Ser Trp Ile Arg His Leu 
145 150 155 160 
Arg Leu Ala Glu Glu Pro Ser Leu Pro Gly Phe Glu Asp Leu Leu Arg 
165 170 175 
Ile Arg Val Glu Pro Asn Thr Ser Pro Leu Ala Asp Lys Asp Glu Lys 
180 185 190 
Ile Phe Arg Phe Gly Ser His Lys Trp Tyr Gly 
195 200 
< 210 > SEQ ID NO 6 
< 211 > LENGTH : 3588 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 6 
gctggaaaga gggcaaggaa agcacgctct ggtgcgactg ccacagtcgc tcaccgcgct 60 
ttgcccgctc gtgaaaccca gcaggccaag aagcacgagg ttgccagcgc caacaaggct 120 
gagcatctca agcactattc cccgcctgcc gacgggaact gtggttggca ctgcatttcc 180 
gccatcgcca accggatggt gaattccaaa tttgaaacca cccttcccga aagagtgaga 240 
ccttcagatg actgggctac tgacgaggat cttgtgaata ccatccaaat cctcaggctc 300 
cctgcggcct tggacaggaa cggtgcttgt gctagcgcca agtacgtgct taagctggaa 360 
ggtgagcatt ggactgtctc tgtgacccct gggatgtccc cttctttgct cccccttgaa 420 
tgtgttcagg gctgttgtga gcataagggc ggtcttggtt ccccagatgc ggtcgaagtt 480 
tccggatttg accctgcctg ccttgaccga ctggotgagg tgatgcactt gcctagcagt 540 
gccatcccag ccgctctggc cgaaatgtcc ggcgacccca atcgtccggc ttccccggtc 600 
accactgtgt ggactgtttc gcagttcttt gcccgtcaca gaggaggaga gcaccctgat 660 
caggtgtgct tagggaaaat catcagcctt tgtcaggtga ttgaggaatg ctgctgttcc 720 
cagaacaaaa ccaaccgggt caccccggaa gaggtcgcgg caaagattga ccagtacctc 780 
cgtggtgcaa caagtcttga agaatgottg gccaggottg agagggctcg cccgccgagc 840 
gcaatggaca cctcctttga ttggaatgtt gtgctccctg gggttgaggc ggcaactcag 900 
acaaccaaac agccccatgt caaccagtgc cgcgctctgg tccctgtcgt gactcaagag 960 
tctttggaca aagactcggt ccctctgacc gccttctcgc tgtctaattg ctactaccct 1020 
gcacaaggtg acgaggttcg tcaccgtgag aggctaaact ccgtgctctc taagttggag 1080 
gaggttgttc gtgaggaata tgggctcacg ccaactggac ctggcccgcg acccgcactg 1140 
ccgaacgggc tcgacgaact taaagaccag atggaggagg atctgctgaa actagtcaac 1200 
goccaggcaa cttcagaaat gatggcctgg gcagccgagc aggttgatct aaaagcttgg 1260 
gtcaaaaact acccacggtg gacaccgcca ccccctccac caagagttca gcctcgaaaa 1320 
acgaagtctg tcaagagctt gccagagaac aagcctgtcc ctgctccgcg caggaaggtc 1380 
agatctgatt gtggcagccc gattttaatg ggcgacaatg tccctaacag ttgggaagat 1440 
ttggctgttg gtggccccct tgatctctcg acaccacccg agccgatgac acctctgagt 1500 
gagcctgcac tta cccgc gttgcaacat atttctaggc cagtgacacc tttgagtgtg 1560 
ccggccccaa ttcctgcacc gcgcagagct gtgtcccgac cggtgacgcc ctcgagtgag 1620 
ccaatttctg tgtctgcacc gcgacataaa tttcagcagg tggaagaagc gaatctggcg 1680 
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gcagcaacgc tgacgtacca ggacgaaccc ctagatttgt ctgcatcctc acagactgaa 1740 
tatgaggett ctcccctagc accactgcag aacatgggta ttctggaggt gggggggcaa 1800 
gaagctgagg aaattctgag tgaaatctcg gacataccga atgacatcaa ccctgcgcct 1860 
gtgtcatcaa gcagctccct gtcaagcgtt aagatcacac gcccaaaata ctcagctcaa 1920 
gccatcatcg actcgggcgg gccctgcagt gggcatctcc aaaaggaaaa agaagcatgo 1980 
ctcagcatca tgcgtgaggc ttgtgatgcg actaagcttg gtgaccctgc cacgcaggaa 2040 
tggctttctc gcatgtggga tagggtggac atgctgactt ggcgcaacac gtctgcttac 2100 
caggcgtttc gcaccttaga tggcaggttt gagtttctcc caaagatgat actcgagaca 2160 
ccgccgccct acccgtgtgg gtttgtgatg ctgcctcaca cgcctgcacc ttccgtgggt 2220 
gcggagagcg accttaccat tggttcagtc gccactgaag atgttccacg catcctcggg 2280 
aaaatagaaa atgccggcga gatgaccaac cagggaccct tggcatcctc cgaggaagaa 2340 
ccggcagacg accaacctgc caaagactcc cggatatcgt cgcgggggtt tgacgagagc 2400 
acagcagctc cgtccgcagg cacaggtggc gccggcttat ttactgattt gccaccttca 2460 
gacggtgtag atgcggacgg gggggggccg ttacagacgg taaaaaagaa agctgaaagg 2520 
ctcttcgacc aattgagccg tcaggttttt aacctcgtct cccatctccc tgttttcttc 2580 
tcacacctct tcaaatctga cagtggttat tctccgggtg attggggttt tgcagctttt 2640 
actctatttt gcctcttttt atgttacagt tacccattct ttggttttgc tcccctcttg 2700 
ggtgtgtttt ctgggtcttc tcggcgcgtg cgcatggggg tttttggctgctggttggct 2760 
tttgctgttg gtctgttcaa gcctgtgtcc gacccagtcg gcactgcttg tgagtttgat 2820 
tcgccagagt gtaggaacgt ccttcattct tttgagcttc tcaaaccttg ggaccctgtt 2880 
cgcagccttg ttgtgggccc cgtcggtctc ggtcttgcca ttcttggcag gttactgggc 2940 
ggggcacgct acatctggca ttttttgctt aggcttggca ttgttgcaga ctgtatcttg 3000 
gctggagctt atgtgctttc tcaaggtagg tgtaaaaagt gctggggatc ttgtataaga 3060 
actgctccta atgagatcgc ctttaacgtg ttccctttta cacgtgcgac caggtcgtca 3120 
ctcatcgacc tgtgcgatcg gttttgtgcg ccaaaaggca tggaccccat tttcctcgcc 3180 
actgggtggc gcgggtgctg gaccggccga agccccattg agcaaccctc tgaaaaaccc 3240 
atcgcgtttg cccagttgga tgaaaagaag attacggcta ggactgtggt cgcccagcct 3300 
tatgacccca accaagccgt aaagtgcttg cgggtgttac aggcgggtgg ggcgatggtg 3360 
gctgaggcag tcccaaaagt ggtcaaggtt tccgctatto cattccgagc cccctttttt 3420 
cccaccggag tgaaagttga ccctgagtgc aggatcgtgg ttgaccccga cactttcact 3480 
acagctctcc ggtctggota ctccaccaca aacctcgtcc ttggtgtggg ggactttgcc 3540 
cagctgaatg gattaaaaat caggcaaatt tccaagcctt caggagga 3588 
< 210 > SEQ ID NO 7 
< 211 > LENGTH : 1196 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 7 
Ala Gly Lys Arg Ala Arg Lys Ala Arg Ser Gly Ala Thr Ala Thr Val 
5 10 15 1 
Ala His Arg Ala Leu Pro Ala Arg Glu Thr Gin Gin Ala Lys Lys His 
20 25 30 
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Glu Val Ala Ser Ala Asn Lys Ala Glu His Leu Lys His Tyr Ser Pro 
35 40 45 
Pro Ala Asp Gly Asn Cys Gly Trp His Cys Ile Ser Ala Ile Ala Asn 
50 55 60 
Arg Met Val Asn Ser Lys Phe Glu Thr Thr Leu Pro Glu Arg Val Arg 
65 70 75 80 
Pro Ser Asp Asp Trp Ala Thr Asp Glu Asp Leu Val Asn Thr Ile Gln 
85 90 95 
Ile Leu Arg Leu Pro Ala Ala Leu Asp Arg Asn Gly Ala Cys Ala Ser 
100 105 110 
Ala Lys Tyr Val Leu Lys Leu Glu Gly Glu His Trp Thr Val Ser Val 
115 120 125 
Thr Pro Gly Met Ser Pro Ser Leu Leu Pro Leu Glu Cys Val Gin Gly 
130 135 140 
Cys Cys Glu His Lys Gly Gly Leu Gly Ser Pro Asp Ala Val Glu Val 
145 150 155 160 
Ser Gly Phe Asp Pro Ala Cys Leu Asp Arg Leu Ala Glu Val Met His 
165 170 175 
Leu Pro Ser Ser Ala Ile Pro Ala Ala Leu Ala Glu Met Ser Gly Asp 
180 185 190 
Pro Asn Arg Pro Ala Ser Pro Val Thr Thr Val Trp Thr Val Ser Gin 
195 200 205 
Phe Phe Ala Arg His Arg Gly Gly Glu His Pro Asp Gin Val Cys Leu 
210 215 220 
Gly Lys Ile Ile Ser Leu Cys Gin Val Ile Glu Glu Cys Cys Cys Ser 
225 230 235 240 
Gln Asn Lys Thr Asn Arg Val Thr Pro Glu Glu Val Ala Ala Lys Ile 
245 250 255 
Asp Gin Tyr Leu Arg Gly Ala Thr Ser Leu Glu Glu Cys Leu Ala Arg 
260 265 270 
Leu Glu Arg Ala Arg Pro Pro Ser Ala Met Asp Thr Ser Phe Asp Trp 
275 280 285 
Asn Val Val Leu Pro Gly Val Glu Ala Ala Thr Gin Thr Thr Lys Gln 
290 295 300 
Pro His Val Asn Gin Cys Arg Ala Leu Val Pro Val Val Thr Gln Glu 
305 310 315 320 
Ser Leu Asp Lys Asp Ser Val Pro Leu Thr Ala Phe Ser Leu Ser Asn 
325 330 335 
Cys Tyr Tyr Pro Ala Gin Gly Asp Glu Val Arg His Arg Glu Arg Leu 
340 345 350 
Asn Ser Val Leu Ser Lys Leu Glu Glu Val Val Arg Glu Glu Tyr Gly 
355 360 365 
Leu Thr Pro Thr Gly Pro Gly Pro Arg Pro Ala Leu Pro Asn Gly Leu 
370 375 380 
Asp Glu Leu Lys Asp Gin Met Glu Glu Asp Leu Leu Lys Leu Val Asn 
385 390 395 400 
Ala Gin Ala Thr Ser Glu Met Met Ala Trp Ala Ala Glu Gin Val Asp 
405 410 415 
Leu Lys Ala Trp Val Lys Asn Tyr Pro Arg Trp Thr Pro Pro Pro Pro 
420 425 430 
Pro Pro Arg Val Gin Pro Arg Lys Thr Lys Ser Val Lys Ser Leu Pro 
435 440 445 
Glu Asn Lys Pro Val Pro Ala Pro Arg Arg Lys Val Arg Ser Asp Cys 
US 10,738,088 B2 
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450 455 460 
Gly Ser Pro Ile Leu Met Gly Asp Asn Val Pro Asn Ser Trp Glu Asp 
465 470 475 480 
Leu Ala Val Gly Gly Pro Leu Asp Leu Ser Thr Pro Pro Glu Pro Met 
485 490 495 
Thr Pro Leu Ser Glu Pro Ala Leu Met Pro Ala Leu Gln His Ile Ser 
500 505 510 
Arg Pro Val Thr Pro Leu Ser Val Pro Ala Pro Ile Pro Ala Pro Arg 
515 520 525 
Arg Ala Val Ser Arg Pro Val Thr Pro Ser Ser Glu Pro Ile Ser Val 
530 535 540 
Ser Ala Pro Arg His Lys Phe Gin Gin Val Glu Glu Ala Asn Leu Ala 
545 550 555 560 
Ala Ala Thr Leu Thr Tyr Gln Asp Glu Pro Leu Asp Leu Ser Ala Ser 
565 570 575 
Ser Gin Thr Glu Tyr Glu Ala Ser Pro Leu Ala Pro Leu Gin Asn Met 
580 585 590 
Gly Ile Leu Glu Val Gly Gly Gin Glu Ala Glu Glu Ile Leu Ser Glu 
595 600 605 
Ile Ser Asp Ile Pro Asn Asp Ile Asn Pro Ala Pro Val Ser Ser Ser 
610 615 620 
Ser Ser Leu Ser Ser Val Lys Ile Thr Arg Pro Lys Tyr Ser Ala Gln 
625 630 635 640 
Ala Ile Ile Asp Ser Gly Gly Pro Cys Ser Gly His Leu Gin Lys Glu 
645 650 655 
Lys Glu Ala Cys Leu Ser Ile Met Arg Glu Ala Cys Asp Ala Thr Lys 
660 665 670 
Leu Gly Asp Pro Ala Thr Gin Glu Trp Leu Ser Arg Met Trp Asp Arg 
675 680 685 
Val Asp Met Leu Thr Trp Arg Asn Thr Ser Ala Tyr Gin Ala Phe Arg 
690 695 700 
Thr Leu Asp Gly Arg Phe Glu Phe Leu Pro Lys Met Ile Leu Glu Thr 
705 710 715 720 
Pro Pro Pro Tyr Pro Cys Gly Phe Val Met Leu Pro His Thr Pro Ala 
725 730 735 
Pro Ser Val Gly Ala Glu Ser Asp Leu Thr Ile Gly Ser Val Ala Thr 
740 745 750 
Glu Asp Val Pro Arg Ile Leu Gly Lys Ile Glu Asn Ala Gly Glu Met 
755 760 765 
Thr Asn Gin Gly Pro Leu Ala Ser Ser Glu Glu Glu Pro Ala Asp Asp 
770 775 780 
Gin Pro Ala Lys Asp Ser Arg Ile Ser Ser Arg Gly Phe Asp Glu Ser 
785 790 795 800 
Thr Ala Ala Pro Ser Ala Gly Thr Gly Gly Ala Gly Leu Phe Thr Asp 
805 810 815 
Leu Pro Pro Ser Asp Gly Val Asp Ala Asp Gly Gly Gly Pro Leu Gin 
820 825 830 
Thr Val Lys Lys Lys Ala Glu Arg Leu Phe Asp Gln Leu Ser Arg Gin 
835 840 845 
Val Phe Asn Leu Val Ser His Leu Pro Val Phe Phe Ser His Leu Phe 
850 855 860 
Lys Ser Asp Ser Gly Tyr Ser Pro Gly Asp Trp Gly Phe Ala Ala Phe 
865 870 875 880 
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Thr Leu Phe Cys Leu Phe Leu Cys Tyr Ser Tyr Pro Phe Phe Gly Phe 
885 890 895 
Ala Pro Leu Leu Gly Val Phe Ser Gly Ser Ser Arg Arg Val Arg Met 
900 905 910 
Gly Val Phe Gly Cys Trp Leu Ala Phe Ala Val Gly Leu Phe Lys Pro 
915 920 925 
Val Ser Asp Pro Val Gly Thr Ala Cys Glu Phe Asp Ser Pro Glu Cys 
930 935 940 
Arg Asn Val Leu His Ser Phe Glu Leu Leu Lys Pro Trp Asp Pro Val 
945 950 955 960 
Arg Ser Leu Val Val Gly Pro Val Gly Leu Gly Leu Ala Ile Leu Gly 
965 970 975 
Arg Leu Leu Gly Gly Ala Arg Tyr Ile Trp His Phe Leu Leu Arg Leu 
980 985 990 
Gly Ile Val Ala Asp Cys Ile Leu Ala Gly Ala Tyr Val Leu Ser Gin 
995 1000 1005 
Thr Ala Pro Gly Arg Cys Lys Lys Cys Trp Gly Ser Cys Ile Arg 
1010 1015 1020 
Asn Glu 
1025 
Ile Ala Phe Asn Val 
1030 
Phe Pro Phe Thr Arg Ala Thr Arg 
1035 
Ser Ser Leu Ile Asp Leu Cys Asp Arg Phe Cys Ala 
1040 1045 1050 
Pro Lys Gly 
Met Asp 
1055 
Pro Ile Phe Leu Ala 
1060 
Thr Gly Trp Arg Gly 
1065 
Cys Trp Thr 
Ile Ala Phe Gly Arg Ser Pro Ile Glu Gln Pro Ser Glu Lys Pro 
1070 1075 1080 
Ala Gin Leu Asp Glu Lys Lys 
1085 1090 




Tyr Asp Pro Asn Gln Ala Val Lys Cys Leu Arg Val Leu 
1105 1110 
Gln Ala Gly Gly Ala Met Val Ala Glu Ala Val Pro Lys Val Val 
1115 1120 1125 
Lys Val 
1130 
Ser Ala Ile Pro Phe 
1135 
Arg Ala Pro Phe Phe Pro Thr Gly 
1140 
Val Lys Val Asp Pro Glu Cys Arg Ile Val Val Asp 
1145 1150 1155 
Pro Asp Thr 
Asn Leu Val Phe Thr 
1160 








Ser Lys Pro Ser Gly 
1195 
Gly 
< 210 > SEQ ID NO 8 
< 211 > LENGTH : 690 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 8 
ggcccacacc tcattgctgc cctgcatgtt gcctgctcga tggcgttgca catgottgct 60 
gggatttatg taactgcagt ggggtcttgo gtaccggca ccaacg cc gtggtgcact 120 
aacccgtttg ccgtccctgg ctacggacct ggctctctct gcacgtccag attgtgcatc 180 
tcccaacatg gccttaccct gcccttgaca gcacttgtgg caggattcgg tcttcaggaa 240 
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attgccttgg ttgttttgat tttcgtttcc atcggaggca tggctcacag gttgagttgc 300 
aaggctgata tgctgtgcgt tttacttgca atcgccagct atgtttgggt accccttacc 360 
tggttgcttt gtgtgtttcc ttgctggttg cgctggttct ctttgcaccc cctcaccato 420 
ctatggttgg tgtttttctt gatttctgta aatatgcctt caggaatctt ggccgtggtg 480 
ttgttggttt ctctttggct tctaggtcgt tatactaatg ttgctggtct tgtcaccccc 540 
tatgacatto atcattacac cagtggcccc cgcggtgttg ccgccttggc taccgcacca 600 
gatgggacct acttggccgc tgtccgccgc gctgcgttga ctggccgcac catgctgttt 660 
accccgtctc agcttgggtc ccttcttgag 690 
< 210 > SEQ ID NO 9 
< 211 > LENGTH : 230 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 9 
Gly Pro His Leu Ile Ala Ala Leu His Val Ala Cys Ser Met Ala Leu 
1 5 10 15 
His Met Leu Ala Gly Ile Tyr Val Thr Ala Val Gly Ser Cys Gly Thr 
20 25 30 
Gly Thr Asn Asp Pro Trp Cys Thr Asn Pro Phe Ala Val Pro Gly Tyr 
35 40 45 
Gly Pro Gly Ser Leu Cys Thr Ser Arg Leu Cys Ile Ser Gin His Gly 
50 55 60 
Leu Thr Leu Pro Leu Thr Ala Leu Val Ala Gly Phe Gly Leu Gln Glu 
75 80 65 70 
Ile Ala Leu Val Val Leu Ile Phe Val Ser Ile Gly Gly Met Ala His 
85 90 95 
Arg Leu Ser Cys Lys Ala Asp Met Leu Cys Val Leu Leu Ala Ile Ala 
100 105 110 
Ser Tyr Val Trp Val Pro Leu Thr Trp Leu Leu Cys Val Phe Pro Cys 
115 120 125 
Trp Leu Arg Trp Phe Ser Leu His Pro Leu Thr Ile Leu Trp Leu Val 
130 135 140 
Phe Phe Leu Ile Ser Val Asn Met Pro Ser Gly Ile Leu Ala Val Val 
145 150 155 160 
Leu Leu Val Ser Leu Trp Leu Leu Gly Arg Tyr Thr Asn Val Ala Gly 
165 170 175 
Leu Val Thr Pro Tyr Asp Ile His His Tyr Thr Ser Gly Pro Arg Gly 
180 185 190 
Val Ala Ala Leu Ala Thr Ala Pro Asp Gly Thr Tyr Leu Ala Ala Val 
195 200 205 
Arg Arg Ala Ala Leu Thr Gly Arg Thr Met Leu Phe Thr Pro Ser Gin 
210 215 220 
Leu Gly Ser Leu Leu Glu 
225 230 
< 210 > SEQ ID NO 10 
< 211 > LENGTH : 612 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 10 
ggtgctttca gaactcaaaa gocctcactg aacaccgtca atgtggtcgg gtcctccatg 60 
US 10,738,088 B2 
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ggctctggcg gggtgttcac catcgacggg aaaattaagt gcgtaactgc cgcacatgtc 120 
cttacgggta attcagctag ggtttccggg gtcggcttca atcaaatgct tgactttgat 180 
gtaaaagggg acttcgccat agctgattgc ccgaattggc aaggggctgc tcccaagacc 240 
caattctgca aggatggatg gactggccgt gcctattggc tgacatcctc tggcgtcgaa 300 
cccggtgtca ttgggaatgg attcgccttc tgcttcaccg cgtgcggcga ttccgggtcc 360 
ccagtgatca ccgaagccgg tgagcttgtc ggcgttcaca caggatcaaa caaacaagga 420 
ggaggcattg tcacgcgccc ctcaggccag ttttgtaatg tggcacccat caagctgagc 480 
gaattaagtg aattctttgc tggacctaag gtcccgctcg gtgatgtgaa ggttggcago 540 
cacataatta aagacataag cgaggtgcct tcagatcttt gcgccttgct tgctgccaaa 600 
cccgaactgg aa 612 
< 210 > SEQ ID NO 11 
< 211 > LENGTH : 204 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 11 
Gly Ala Phe Arg Thr Gin Lys Pro Ser Leu Asn Thr Val Asn Val Val 
10 15 1 5 
Gly Ser Ser Met Gly Ser Gly Gly Val Phe Thr Ile Asp Gly Lys Ile 
20 25 30 
Lys Cys Val Thr Ala Ala His Val Leu Thr Gly Asn Ser Ala Arg Val 
35 45 40 
Ser Gly Val Gly Phe Asn Gin Met Leu Asp Phe Asp Val Lys Gly Asp 
50 55 60 
Phe Ala Ile Ala Asp Cys Pro Asn Trp Gin Gly Ala Ala Pro Lys Thr 
65 70 75 80 
Gln Phe Cys Lys Asp Gly Trp Thr Gly Arg Ala Tyr Trp Leu Thr Ser 
85 90 95 
Ser Gly Val Glu Pro Gly Val Ile Gly Asn Gly Phe Ala Phe Cys Phe 
100 105 110 
Thr Ala Cys Gly Asp Ser Gly Ser Pro Val Ile Thr Glu Ala Gly Glu 
115 120 125 
Leu Val Gly Val His Thr Gly Ser Asn Lys Gin Gly Gly Gly Ile Val 
130 135 140 
Thr Arg Pro Ser Gly Gin Phe Cys Asn Val Ala Pro Ile Lys Leu Ser 
145 150 155 160 
Glu Leu Ser Glu Phe Phe Ala Gly Pro Lys Val Pro Leu Gly Asp Val 
165 170 175 
Lys Val Gly Ser His Ile Ile Lys Asp Ile Ser Glu Val Pro Ser Asp 
180 185 190 
Leu Cys Ala Leu Leu Ala Ala Lys Pro Glu Leu Glu 
195 200 
< 210 > SEQ ID NO 12 
< 211 > LENGTH : 510 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 12 
ggaggcctct ccaccgtcca acttctgtgt gtgtttttcc tcctgtggag aatgatggga 60 
catgcctgga cgcccttggt tgctgtgggt ttttttatct tgaatgaggt tctcccagct 120 
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49 50 
- continued 
gtcctggtcc ggagtgtttt ctcctttgga atgtttgtgc tatcttggct cacaccatgg 180 
tctgcgcaag ttctgatgat caggcttcta acagcagctc ttaacaggaa cagatggtca 240 
cttgcctttt acagcctcgg tgcagtgacc ggttttgtcg cagatcttgc ggcaactcag 300 
gggcatccgt tgcaggcagt gatgaattta agcacctatg ccttcctgcc tcggatgatg 360 
gttgtgacct caccagtccc agtgattgcg tgtggtgttg tgcacctcct toccataatt 420 
ttgtacttgt ttaagtaccg ttgcctgcac aatgtccttg ttggcgatgg agtgttctct 480 
gcggctttct tcttgcgata ctttgccgag 510 
< 210 > SEQ ID NO 13 
< 211 > LENGTH : 170 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 13 
Gly Gly Leu Ser Thr Val Gin Leu Leu Cys Val Phe Phe Leu Leu Trp 
1 5 10 15 
Arg Met Met Gly His Ala Trp Thr Pro Leu Val Ala Val Gly Phe Phe 
20 25 30 
Ile Leu Asn Glu Val Leu Pro Ala Val Leu Val Arg Ser Val Phe Ser 
40 45 35 
Phe Gly Met Phe Val Leu Ser Trp Leu Thr Pro Trp Ser Ala Gin Val 
50 55 60 
Leu Met Ile Arg Leu Leu Thr Ala Ala Leu Asn Arg Asn Arg Trp Ser 
65 70 75 80 
Leu Ala Phe Tyr Ser Leu Gly Ala Val Thr Gly Phe Val Ala Asp Leu 
85 95 90 
Ala Ala Thr Gin Gly His Pro Leu Gin Ala Val Met Asn Leu Ser Thr 
100 105 110 
Tyr Ala Phe Leu Pro Arg Met Met Val Val Thr Ser Pro Val Pro Val 
115 120 125 
Ile Ala Cys Gly Val Val His Leu Leu Ala Ile Ile Leu Tyr Leu Phe 
130 135 140 
Lys Tyr Arg Cys Leu His Asn Val Leu Val Gly Asp Gly Val Phe Ser 
145 150 155 160 
Ala Ala Phe Phe Leu Arg Tyr Phe Ala Glu 
165 170 
< 210 > SEQ ID NO 14 
< 211 > LENGTH : 48 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 14 
ggaaagttga gggaaggggt gtcgcaatcc tgcgggatga atcatgag 48 
< 210 > SEQ ID NO 15 
< 211 > LENGTH : 16 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 15 
Gly Lys Leu Arg Glu Gly Val Ser Gin Ser Cys Gly Met Asn His Glu 
5 10 15 1 
< 210 > SEQ ID NO 16 
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< 211 > LENGTH : 777 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 16 
tcactgactg gtgccctcgc tatgagactc aatgacgagg acttggattt ccttacgaaa 60 
tggactgatt ttaagtgctt tgtttctgcg tccaacatga ggaatgcagc gggccaattc 120 
atcgaggctg cctatgctaa agcacttaga gtagaacttg cccagttggt gcaggttgat 180 
aaggttcgag gtactttggc caaacttgaa gcttttgctg ataccgtggc accccaactc 240 
tcgcccggtg acattgttgt tgctcttggc cacacgcctg ttggcagtat cttcgaccta 300 
aaggttggta gcaccaagca taccctccaa gccattgaga ccagagtcct tgccgggtcc 360 
aaaatgaccg tggcgcgcgt cgttgaccca acccccacgc ccccacccgc acccgtgccc 420 
atccccctcc caccgaaagt tctggagaat ggccccaacg cctgggggga tgaggaccgt 480 
ttgaataaga agaagaggcg caggatggaa gccgtcggca tctttgttat gggcgggaag 540 
aagtaccaga aattttggga caagaattcc ggtgatgtgt tttatgagga ggtccatgat 600 
aacacagatg cgtgggagtg cctcagagtt ggcgaccctg ccgactttga ccctgagaag 660 
ggaactctgt gtgggcatac caccattgaa gataaggctt acaatgtcta cgcctcccca 720 
tctggcaaga agttcctggt ccccgtcaac ccagagagcg gaagagccca atgggaa 777 
< 210 > SEQ ID NO 17 
< 211 > LENGTH : 259 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 17 
Ser Leu Thr Gly Ala Leu Ala Met Arg Leu Asn Asp Glu Asp Leu Asp 
1 10 15 5 
Phe Leu Thr Lys Trp Thr Asp Phe Lys Cys Phe Val Ser Ala Ser Asn 
20 25 30 
Met Arg Asn Ala Ala Gly Gin Phe Ile Glu Ala Ala Tyr Ala Lys Ala 
35 40 45 
Leu Arg Val Glu Leu Ala Gin Leu Val Gin Val Asp Lys Val Arg Gly 
50 55 60 
Thr Leu Ala Lys Leu Glu Ala Phe Ala Asp Thr Val Ala Pro Gin Leu 
65 70 75 80 
Ser Pro Gly Asp Ile Val Val Ala Leu Gly His Thr Pro Val Gly Ser 
85 90 95 
Ile Phe Asp Leu Lys Val Gly Ser Thr Lys His Thr Leu Gin Ala Ile 
100 105 110 
Glu Thr Arg Val Leu Ala Gly Ser Lys Met Thr Val Ala Arg Val Val 
115 120 125 
Asp Pro Thr Pro Thr Pro Pro Pro Ala Pro Val Pro Ile Pro Leu Pro 
130 135 140 
Pro Lys Val Leu Glu Asn Gly Pro Asn Ala Trp Gly Asp Glu Asp Arg 
145 150 155 160 
Leu Asn Lys Lys Lys Arg Arg Arg Met Glu Ala Val Gly Ile Phe Val 
165 170 175 
Met Gly Gly Lys Lys Tyr Gln Lys Phe Trp Asp Lys Asn Ser Gly Asp 
180 185 190 
Val Phe Tyr Glu Glu Val His Asp Asn Thr Asp Ala Trp Glu Cys Leu 
195 200 205 
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Arg Val Gly Asp Pro Ala Asp Phe Asp Pro Glu Lys Gly Thr Leu Cys 
210 215 220 
Gly His Thr Thr Ile Glu Asp Lys Ala Tyr Asn Val Tyr Ala Ser Pro 
225 230 235 240 
Ser Gly Lys Lys Phe Leu Val Pro Val Asn Pro Glu Ser Gly Arg Ala 
245 250 255 
Gin Trp Glu 
< 210 > SEQ ID NO 18 
< 211 > LENGTH : 138 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 18 
gctgcaaagc tttccgtgga gcaggccctt ggcatgatga atgtcgacgg tgaactgaca 60 
gccaaagaac tggagaaact gaaaagaata attgacaaac tccagggcct gactaaggag 120 
cagtgtttaa actgctag 138 
< 210 > SEQ ID NO 19 
< 211 > LENGTH : 45 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 19 
Ala Ala Lys Leu Ser Val Glu Gln Ala Leu Gly Met Met Asn Val Asp 
1 5 10 15 
Gly Glu Leu Thr Ala Lys Glu Leu Glu Lys Leu Lys Arg Ile Ile Asp 
20 25 30 
Lys Leu Gin Gly Leu Thr Lys Glu Gin Cys Leu Asn Cys 
35 40 45 
< 210 > SEQ ID NO 20 
< 211 > LENGTH : 1917 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 20 
gccgccagcg gottgacccg ctgtggtcgc ggcggcttgg ttgttactga gacagcggta 60 
aaaatagtca aatttcacaa ccggaccttc accctaggac ctgtgaattt aaaagtggcc 120 
agtgaggttg agctaaaaga cgcggtcgag cacaaccaac acccggttgc aagaccggtt 180 
gatggtggtg ttgtgctcct gcgctccgca gttccttcgc ttatagacgt cttgatctcc 240 
ggtgctgatg catctcccaa gttactcgcc cgccacgggc cgggaaacac tgggatcgat 300 
ggcacgcttt gggattttga ggccgaagcc accaaagagg aaatcgcact cagtgcgcaa 360 
ataatacagg cttgtgacat taggcgcggc gacgcacctg aaattggtct cccttacaag 420 
ctgtaccctg ttaggggcaa ccctgagcgg gtaaaaggag ttttgcagaa tacaaggttt 480 
ggagacatac cttacaaaac ccccagtgac actggaagcc cagtgcacgc ggctgcctgc 540 
ctcacgccca atgccactcc ggtgactgat gggcgctccg tcttggccac gaccatgccc 600 
tccggttttg agttgtatgt accgaccatt ccagcgtctg tccttgatta tcttgattct 660 
aggcctgact gccccaaaca gttgacagag cacggctgtg aggatgccgc attgagagac 720 
ctctccaagt gtc cacccaaggc tttgttttgc ctggagttct tcgccttgtg 780 
cgtaagtacc tgtttgccca tgtgggtaag tgcccgcccg ttcatcggcc ttccacttac 840 
cctgccaaga attctatggc tggaataaat gggaacaggt ttccaaccaa ggacattcag 900 
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agcgtccctg aaatcgacgt tctgtgcgca caggccgtgc gagaaaactg gcaaactgtt 960 
accccttgta ccctcaagaa acagtattgc gggaagaaga agactaggac aatactcggc 1020 
accaataact tcattgcgct ggcccaccgg gcagcgttga gtggtgtcac ccagggcttc 1080 
atgaaaaagg cgtttaactc gcccatcgcc ctcgggaaaa acaaatttaa ggagctacag 1140 
actccggtct tgggcaggtg ccttgaagct gatcttgcat cctgcgatcg atccacacct 1200 
gcaattgtcc gctggtttgc cgccaatctt ctttatgaac ttgcctgtgc tgaagagcat 1260 
ctaccgtcgt acgtgctgaa ctgctgccac gacttactgg tcacgcagtc cggcgcagtg 1320 
actaagagag gtggcctgtc gtctggcgac ccgatcactt ctgtgtccaa caccatttac 1380 
agcttggtga tatatgcaca gcacatggtg ctcagttact ttaaaagtgg tcacccccat 1440 
ggccttctgt ttctacaaga ccagctaaag tttgaggaca tgctcaaggt tcaacccctg 1500 
atcgtctatt cggacgacct cgtgctgtat gccgagtctc ccaccatgcc aaactaccac 1560 
tggtgggttg aacatctgaa cctgatgctg ggttttcaga cggacccaaa gaagacagcc 1620 
ataacagact cgccatcatt tctaggctgt aggataataa atgggcgcca gctagtcccc 1680 
aaccgtgaca ggattctcgc ggccctcgcc taccacatga aggcgagcaa tgtttctgaa 1740 
tactacgcct cggcggctgc aatactcatg gacagctgtg cttgtttgga gtatgatcct 1800 
gaatggtttg aagaacttgt ggttggaata gcgcagtgcg cccgcaagga cggctacago 1860 
tttcccggcc cgccgttctt cttgtccatg tgggaaaaac tcaggtccaa ttatgag 1917 
< 210 > SEQ ID NO 21 
< 211 > LENGTH : 639 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 21 
Ala Ala Ser Gly Leu Thr Arg Cys Gly Arg Gly Gly Leu Val Val Thr 
1 5 10 15 
Glu Thr Ala Val Lys Ile Val Lys Phe His Asn Arg Thr Phe Thr Leu 
20 25 30 
Gly Pro Val Asn Leu Lys Val Ala Ser Glu Val Glu Leu Lys Asp Ala 
35 40 45 
Val Glu His Asn Gin His Pro Val Ala Arg Pro Val Asp Gly Gly Val 
50 55 60 
Val Leu Leu Arg Ser Ala Val Pro Ser Leu Ile Asp Val Leu Ile Ser 
65 70 75 80 
Gly Ala Asp Ala Ser Pro Lys Leu Leu Ala Arg His Gly Pro Gly Asn 
85 90 95 
Thr Gly Ile Asp Gly Thr Leu Trp Asp Phe Glu Ala Glu Ala Thr Lys 
100 105 110 
Glu lu Ile Ala Leu Ser Ala Gln Ile Ile Gln Ala Cys Asp Ile Arg 
115 120 125 
Arg Gly Asp Ala Pro Glu Ile Gly Leu Pro Tyr Lys Leu Tyr Pro Val 
130 135 140 
Arg Gly Asn Pro Glu Arg Val Lys Gly Val Leu Gin Asn Thr Arg Phe 
145 150 155 160 
Gly Asp Ile Pro Tyr Lys Thr Pro Ser Asp Thr Gly Ser Pro Val His 
165 170 175 
Ala Ala Ala Cys Leu Thr Pro Asn Ala Thr Pro Val Thr Asp Gly Arg 
180 185 190 
US 10,738,088 B2 
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Ser Val Leu Ala Thr Thr Met Pro Ser Gly Phe Glu Leu Tyr Val Pro 
195 200 205 
Thr Ile Pro Ala Ser Val Leu Asp Tyr Leu Asp Ser Arg Pro Asp Cys 
210 215 220 
Pro Lys Gln Leu Thr Glu His Glycys Glu Asp Ala Ala Leu Arg Asp 
225 230 235 240 
Leu Ser Lys Tyr Asp Leu Ser Thr Gin Gly Phe Val Leu Pro Gly Val 
245 250 255 
Leu Arg Leu Val Arg Lys Tyr Leu Phe Ala His Val Gly Lys Cys Pro 
260 265 270 
Pro Val His Arg Pro Ser Thr Tyr Pro Ala Lys Asn Ser Met Ala Gly 
275 280 285 
Ile Asn Gly Asn Arg Phe Pro Thr Lys Asp Ile Gin Ser Val Pro Glu 
290 295 300 
Ile Asp Val Leu Cys Ala Gln Ala Val Arg Glu Asn Trp Gln Thr Val 
305 310 315 320 
Thr Pro Cys Thr Leu Lys Lys Gin Tyr Cys Gly Lys Lys Lys Thr Arg 
325 330 335 
Thr Ile Leu Gly Thr Asn Asn Phe Ile Ala Leu Ala His Arg Ala Ala 
340 345 350 
Leu Ser Gly Val Thr Gin Gly Phe Met Lys Lys Ala Phe Asn Ser Pro 
355 360 365 
Ile Ala Leu Gly Lys Asn Lys Phe Lys Glu Leu Gin Thr Pro Val Leu 
370 375 380 
Gly Arg Cys Leu Glu Ala Asp Leu Ala Ser Cys Asp Arg Ser Thr Pro 
385 390 395 400 
Ala Ile Val Arg Trp Phe Ala Ala Asn Leu Leu Tyr Glu Leu Ala Cys 
405 410 415 
Ala Glu Glu His Leu Pro Ser Tyr Val Leu Asn Cys Cys His Asp Leu 
420 425 430 
Leu Val Thr Gln Ser Gly Ala Val Thr Lys Arg Gly Gly Leu Ser Ser 
435 440 445 
Gly Asp Pro Ile Thr Ser Val Ser Asn Thr Ile Tyr Ser Leu Val Ile 
450 455 460 
Tyr Ala Gln His Met Val Leu Ser Tyr Phe Lys Ser Gly His Pro His 
465 470 475 480 
Gly Leu Leu Phe Leu Gln Asp Gln Leu Lys Phe Glu Asp Met Leu Lys 
485 490 495 
Val Gin Pro Leu Ile Val Tyr Ser Asp Asp Leu Val Leu Tyr Ala Glu 
500 505 510 
Ser Pro Thr Met Pro Asn Tyr His Trp Trp Val Glu His Leu Asn Leu 
515 520 525 
Met Leu Gly Phe Gin Thr Asp Pro Lys Lys Thr Ala Ile Thr Asp Ser 
530 535 540 
Pro Ser Phe Leu Gly Cys Arg Ile Ile Asn Gly Arg Gin Leu Val Pro 
545 550 555 560 
Asn Arg Asp Arg Ile Leu Ala Ala Leu Ala Tyr His Met Lys Ala Ser 
565 570 575 
Asn Val Ser Glu Tyr Tyr Ala Ser Ala Ala Ala Ile Leu Met Asp Ser 
580 585 590 
Cys Ala Cys Leu Glu Tyr Asp Pro Glu Trp Phe Glu Glu Leu Val Val 
595 600 605 
Gly Ile Ala Gln Cys Ala Arg Lys Asp Gly Tyr Ser Phe Pro Gly Pro 
US 10,738,088 B2 
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610 615 620 
Pro Phe Phe Leu Ser Met Trp Glu Lys Leu Arg Ser Asn Tyr Glu 
625 630 635 
< 210 > SEQ ID NO 22 
< 211 > LENGTH : 1323 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 22 
gggaagaagt ccagagtgtg cgggtactgc ggggccccgg ccccgtacgc cactgcctgt 60 
ggcctcgacg tctgtattta ccacacccac ttccaccagc attgtccagt cataatctgg 120 
tgtggccatc cagcgggttc tggttcttgt agtgagtgca aaccccccct agggaaaggc 180 
acaagccctc tagatgaggt gttggaacaa gtcccgtata agcctccacg gaccgtaatc 240 
atgcatgtgg agcagggtct cacccctctt gacccaggca gataccagac tcgccgcgga 300 
ttagtctccg ttaggcgtgg catcagggga aatgaagttg acctaccaga cggtgattat 360 
gctagcaccg ccttgctccc cacttgtaaa gagatcaaca tggtcgctgt cgcttctaat 420 
gtgttgcgca gcaggttcat catcggtcca cccggtgctg ggaaaacata ctggctcctt 480 
caacaggtcc aggatggtga tgtcatttac acaccaactc atcagaccat gottgacatg 540 
attaaggett tggggacgtg ccggttcaac gtcccggcag gcacaacgct gcaattccct 600 
gccccctccc gtaccggccc gtgggttcgc atcctggccg gcggttggtg tcctggcaag 660 
aattccttcc tggatgaagc agcgtattgt aatcaccttg atgtcttgag gottcttago 720 
aaaactaccc tcacctgtct gggagacttc aaacaactcc acccagtggg ttttgattct 780 
cattgctatg tttttgacat catgcctcag actcaactga agaccatctg gaggtttgga 840 
cagaatatct gtgatgccat tcagccagat tacagggaca aacttgtgtc catggtcaac 900 
acaacccgtg taacctacgt ggaaaaacct gtcaagtatg ggcaagtcct caccccttac 960 
cacagggacc gagaggacgg cgccatcaca attgactcca gtcaaggcgc cacatttgat 1020 
gtggttacat tgcatttgcc cactaaagat tcactcaaca ggcaaagagc ccttgttgct 1080 
atcaccaggg caagacatgc tatctttgtg tatgacccac acaggcaact gcagagcatg 1140 
tttgatcttc ctgcaaaagg cacacccgtc aacctcgccg tgcaccgtga cgagcagctg 1200 
atcgtgctag atagaaataa caaagaatgc acggttgctc aggctctagg caatggggat 1260 
aaattcaggg ccacagacaa gcgcgttgta gattctctcc gcgccatttg tgcagatcta 1320 
gaa 1323 
< 210 > SEQ ID NO 23 
< 211 > LENGTH : 441 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 23 
Gly Lys Lys Ser Arg Val Cys Gly Tyr Cys Gly Ala Pro Ala Pro Tyr 
5 10 15 1 
Ala Thr Ala Cys Gly Leu Asp Val Cys Ile Tyr His Thr His Phe His 
20 25 30 
Gin His Cys Pro Val Ile Ile Trp Cys Gly His Pro Ala Gly Ser Gly 
35 40 45 
Ser Cys Ser Glu Cys Lys Pro Pro Leu Gly Lys Gly Thr Ser Pro Leu 
50 55 60 
US 10,738,088 B2 
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Asp Glu Val Leu Glu Gin Val Pro Tyr Lys Pro Pro Arg Thr Val Ile 
65 70 75 80 
Met His Val Glu Gin Gly Leu Thr Pro Leu Asp Pro Gly Arg Tyr Gin 
85 90 95 
Thr Arg Arg Gly Leu Val Ser Val Arg Arg Gly Ile Arg Gly Asn Glu 
100 105 110 
Val Asp Leu Pro Asp Gly Asp Tyr Ala Ser Thr Ala Leu Leu Pro Thr 
115 120 125 
Cys Lys Glu Ile Asn Met Val Ala Val Ala Ser Asn Val Leu Arg Ser 
130 135 140 
Arg Phe Ile Ile Gly Pro Pro Gly Ala Gly Lys Thr Tyr Trp Leu Leu 
145 150 155 160 
Gin Gin Val Gln Asp Gly Asp Val Ile Tyr Thr Pro Thr His Gin Thr 
165 170 175 
Met Leu Asp Met Ile Lys Ala Leu Gly Thr Cys Arg Phe Asn Val Pro 
180 185 190 
Ala Gly Thr Thr Leu Gin Phe Pro Ala Pro Ser Arg Thr Gly Pro Trp 
195 200 205 
Val Arg Ile Leu Ala Gly Gly Trp Cys Pro Gly Lys Asn Ser Phe Leu 
210 215 220 
Asp Glu Ala Ala Tyr Cys Asn His Leu Asp Val Leu Arg Leu Leu Ser 
225 230 235 240 
Lys Thr Thr Leu Thr Cys Leu Gly Asp Phe Lys Gin Leu His Pro Val 
245 250 255 
Gly Phe Asp Ser His Cys Tyr Val Phe Asp Ile Met Pro Gin Thr Gln 
260 265 270 
Leu Lys Thr Ile Trp Arg Phe Gly Gln Asn Ile Cys Asp Ala Ile Gin 
275 280 285 
Pro Asp Tyr Arg Asp Lys Leu Val Ser Met Val Asn Thr Thr Arg Val 
290 295 300 
Thr Tyr Val Glu Lys Pro Val Lys Tyr Gly Gln Val Leu Thr Pro Tyr 
305 310 315 320 
His Arg Asp Arg Glu Asp Gly Ala Ile Thr Ile Asp Ser Ser Gin Gly 
325 330 335 
Ala Thr Phe Asp Val Val Thr Leu His Leu Pro Thr Lys Asp Ser Leu 
340 345 350 
Asn Arg Gin Arg Ala Leu Val Ala Ile Thr Arg Ala Arg His Ala Ile 
355 360 365 
Phe Val Tyr Asp Pro His Arg Gin Leu Gin Ser Met Phe Asp Leu Pro 
370 375 380 
Ala Lys Gly Thr Pro Val Asn Leu Ala Val His Arg Asp Glu Gln Leu 
385 390 395 400 
Ile Val Leu Asp Arg Asn Asn Lys Glu Cys Thr Val Ala Gin Ala Leu 
405 410 415 
Gly Asn Gly Asp Lys Phe Arg Ala Thr Asp Lys Arg Val Val Asp Ser 
420 425 430 
Leu Arg Ala Ile Cys Ala Asp Leu Glu 
435 440 
< 210 > SEQ ID NO 24 
< 211 > LENGTH : 669 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 24 
US 10,738,088 B2 
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gggtcgagct ctccgctccc caaggtcgca cacaacttgg gattttattt ctcacctgat 60 
ttgacacagt ttgctaaact cccggtagaa cttgcacccc actggcccgt ggtgacaacc 120 
cagaacaatg aaaagtggcc agaccggctg gttgccagcc ttcgccctat ccataaatat 180 
agccgcgcgt gcatcggtgc cggctatatg gtgggcccct cggtgtttct aggcacccct 240 
ggggttgtgt catactatct cacaaaattt gttaagggcg aggctcaagt gottccggag 300 
acagtcttca gcaccggccg aattgaggta gattgccggg agtatcttga tgatcgggag 360 
cgagaagttg ctgagtccct cccacatgcc ttcattggcg acgtcaaagg cactaccgtt 420 
ggaggatgtc accatgtcac ctccaaatac cttccgcgct tccttcccaa ggaatcagtt 480 
gcggtagtcg gggtttcaag ccccgggaaa gccgcaaaag cagtttgcac attaacagat 540 
gtgtacctcc cagaccttga agcttacctc cacccagaga cccagtccaa gtgctggaaa 600 
atgatgttgg acttcaagga agttcgactg atggtctgga aagacaaaac ggcctatttt 660 
caacttgaa 669 
< 210 > SEQ ID NO 25 
< 211 > LENGTH : 223 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 25 
Gly Ser Ser Ser Pro Leu Pro Lys Val Ala His Asn Leu Gly Phe Tyr 
1 5 10 15 
Phe Ser Pro Asp Leu Thr Gln Phe Ala Lys Leu Pro Val Glu Leu Ala 
20 25 30 
Pro His Trp Pro Val Val Thr Thr Gin Asn Asn Glu Lys Trp Pro Asp 
35 40 45 
Arg Leu Val Ala Ser Leu Arg Pro Ile His Lys Tyr Ser Arg Ala Cys 
50 55 60 
Ile Gly Ala Gly Tyr Met Val Gly Pro Ser Val Phe Leu Gly Thr Pro 
65 70 75 80 
Gly Val Val Ser Tyr Tyr Leu Thr Lys Phe Val Lys Gly Glu Ala Gin 
85 90 95 
Val Leu Pro Glu Thr Val Phe Ser Thr Gly Arg Ile Glu Val Asp Cys 
100 105 110 
Arg Glu Tyr Leu Asp Asp Arg Glu Arg Glu Val Ala Glu Ser Leu Pro 
115 120 125 
His Ala Phe Ile Gly Asp Val Lys Gly Thr Thr Val Gly Gly Cys His 
130 135 140 
His Val Thr Ser Lys Tyr Leu Pro Arg Phe Leu Pro Lys Glu Ser Val 
145 150 155 160 
Ala Val Val Gly Val Ser Ser Pro Gly Lys Ala Ala Lys Ala Val Cys 
165 170 175 
Thr Leu Thr Asp Val Tyr Leu Pro Asp Leu Glu Ala Tyr Leu His Pro 
180 185 190 
Glu Thr Gin Ser Lys Cys Trp Lys Met Met Leu Asp Phe Lys Glu Val 
195 200 205 
Arg Leu Met Val Trp Lys Asp Lys Thr Ala Tyr Phe Gin Leu Glu 
210 215 220 
< 210 > SEQ ID NO 26 
< 211 > LENGTH : 462 
< 212 > TYPE : DNA 
US 10,738,088 B2 
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< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 26 
ggccgccatt tcacctggta tcagcttgca agctatgcct cgtacatccg agttcctgtt 60 
aactctacgg tgtatttgga cccctgcatg ggccctgccc tttgcaacag aagagttgtc 120 
gggtccactc attggggggc tgacctcgca gtcacccctt atgattatgg tgccaaaatc 180 
attctgtcta gtgcatacca tggtgaaatg cctcctgggt acaaaatcct ggcgtgcgcg 240 
gagttctcgc ttgacgatcc agtgaggtac aaacacacct gggggtttga atcggataca 300 
gcgtatctgt acgagttcac cggaaacggt gaggactggg aggattacaa tgatgcgttt 360 
cgtgcgcgcc agaaagggaa aatttataag gccactgcca ccagcatgag gtttcatttt 420 
cccccgggcc ctgtcattga accaactttg ggcctgaatt ga 462 
< 210 > SEQ ID NO 27 
< 211 > LENGTH : 153 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 27 
Gly Arg His Phe Thr Trp Tyr Gln Leu Ala Ser Tyr Ala Ser Tyr Ile 
1 5 10 15 
Arg Val Pro Val Asn Ser Thr Val Tyr Leu Asp Pro Cys Met Gly Pro 
20 25 30 
Ala Leu Cys Asn Arg Arg Val Val Gly Ser Thr His Trp Gly Ala Asp 
35 40 45 
Leu Ala Val Thr Pro Tyr Asp Tyr Gly Ala Lys Ile Ile Leu Ser Ser 
50 55 60 
Ala Tyr His Gly Glu Met Pro Pro Gly Tyr Lys Ile Leu Ala Cys Ala 
65 70 75 80 
Glu Phe Ser Leu Asp Asp Pro Val Arg Tyr Lys His Thr Trp Gly Phe 
85 95 90 
Glu Ser Asp Thr Ala Tyr Leu Tyr Glu Phe Thr Gly Asn Gly Glu Asp 
100 105 110 
Trp Glu Asp Tyr Asn Asp Ala Phe Arg Ala Arg Gin Lys Gly Lys Ile 
115 120 125 
Tyr Lys Ala Thr Ala Thr Ser Met Arg Phe His Phe Pro Pro Gly Pro 
130 135 140 
Val Ile Glu Pro Thr Leu Gly Leu Asn 
145 150 
< 210 > SEQ ID NO 28 
< 211 > LENGTH : 771 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 28 
atgaaatggg ggctatgcaa agcctttttg acaaaattgg ccaacttttt gtggatgott 60 
tcacggaatt tttggtgtcc attgttgata tcatcatatt tttggccatt ttgtttggct 120 
tcaccatcgc cggttggctg gtggtctttt gcatcagatt ggtttgctcc gcggtactcc 180 
gtgcgcgccc taccattcac cctgagcaat tacagaagat cctatgaggc ctttctttct 240 
ca gccggg cggacattcc cacctgggga actaaacatc ccttggggat ggcac 300 
cataaggtgt caaccctgat tgatgaaatg gtgtcgcgtc gaatgtaccg catcatggaa 360 
aaagcaggac aggctgcctg gaaacaggtg gtgagcgagg ctacgctgtc tcgcattagt 420 
US 10,738,088 B2 
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ggtttggatg tggtggctca ttttcagcat cttgccgcca ttgaagccga gacctgtaaa 480 
tatttggcct ctcggctgcc catgctacac aacctgcgca tgacagggtc aaatgtaacc 540 
atagtgtata atagtacttt gaatcaggtg tttgctattt ttccaacccc tggttcccgg 600 
ccaaagcttc atgattttca gcaatggcta atagctgtgc attcctccat attttcctct 660 
gttgcagctt cttgtactct ttttgttgtg ctgtggttgc ggattccaat gctacgtact 720 
gtttttggtt tccactggtt aggggcaatt tttccttcga actcacagtg a 771 
< 210 > SEQ ID NO 29 
< 211 > LENGTH : 256 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 29 
Met Lys Trp Gly Leu Cys Lys Ala Phe Leu Thr Lys Leu Ala Asn Phe 
1 10 15 5 
Leu Trp Met Leu Ser Arg Asn Phe Trp Cys Pro Leu Leu Ile Ser Ser 
20 25 30 
Tyr Phe Trp Pro Phe Cys Leu Ala Ser Pro Ser Pro Val Gly Trp Trp 
35 40 45 
Ser Phe Ala Ser Asp Trp Phe Ala Pro Arg Tyr Ser Val Arg Ala Leu 
50 55 60 
Pro Phe Thr Leu Ser Asn Tyr Arg Arg Ser Tyr Glu Ala Phe Leu Ser 
65 70 75 80 
Gin Cys Arg Val Asp Ile Pro Thr Trp Gly Thr Lys His Pro Leu Gly 
85 90 95 
Met Leu Trp His His Lys Val Ser Thr Leu Ile Asp Glu Met Val Ser 
100 105 110 
Arg Arg Met Tyr Arg Ile Met Glu Lys Ala Gly Gin Ala Ala Trp Lys 
115 120 125 
Gin Val Val Ser Glu Ala Thr Leu Ser Arg Ile Ser Gly Leu Asp Val 
130 135 140 
Val Ala His Phe Gin His Leu Ala Ala Ile Glu Ala Glu Thr Cys Lys 
145 150 155 160 
Tyr Leu Ala Ser Arg Leu Pro Met Leu His Asn Leu Arg Met Thr Gly 
165 170 175 
Ser Asn Val Thr Ile Val Tyr Asn Ser Thr Leu Asn Gin Val Phe Ala 
180 185 190 
Ile Phe Pro Thr Pro Gly Ser Arg Pro Lys Leu His Asp Phe Gln Gln 
195 200 205 
Trp Leu Ile Ala Val His Ser Ser Ile Phe Ser Ser Val Ala Ala Ser 
210 215 220 
Cys Thr Leu Phe Val Val Leu Trp Leu Arg Ile Pro Met Leu Arg Thr 
225 230 235 240 
Val Phe Gly Phe His Trp Leu Gly Ala Ile Phe Pro Ser Asn Ser Gin 
245 250 255 
< 210 > SEQ ID NO 30 
< 211 > LENGTH : 765 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 30 
atggctaata gctgtgcatt cctccatatt ttcctctgtt gcagcttctt gtactctttt 60 
US 10,738,088 B2 
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tgttgtgctg tggttgcgga ttccaatgct acgtactgtt tttggtttcc actggttagg 120 
ggcaattttt ccttcgaact cacagtgaat tacacggtgt gtccaccttg cctcacccgg 180 
caagcagccg ctgagatcta cgaacccggc aggtctcttt ggtgcaggat agggcatgac 240 
cgatgtaggg aggacgatca tgacgaacta gggttcatgg ttccgcctgg cctctccagc 300 
gaaggccact tgaccagtgt ttacgcctgg ttggcgttcc tgtccttcag ctacacggcc 360 
cagttccato ccgagatatt tgggataggg aatgtgagtc aagtttatgt tgacatcaag 420 
caccaattca tctgcgccga acatgacggg cagaacgcca ccttgcctcg ccatgacaac 480 
atttcagccg tgtttcagac ctactaccaa catcaggtcg acggcggcaa ttggtttcac 540 
ctagaatggc tgcgcccctt cttttcctct tggttggttt taaatgtttc gtggtttctc 600 
aggcgttcgc ctgcaagcca tgtttcagtt cgagtctttc agacatcaag accaacacca 660 
ccgcagcage aagctttgtt gtcctccaag acatcagctg ccttaggcat ggcgactcgt 720 
cctctgaggo gattcgcaaa agctctcagt gccgcacggc gatag 765 
< 210 > SEQ ID NO 31 
< 211 > LENGTH : 254 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 31 
Met Ala Asn Ser Cys Ala Phe Leu His Ile Phe Leu Cys Cys Ser Phe 
1 5 10 15 
Leu Tyr Ser Phe Cys Cys Ala Val Val Ala Asp Ser Asn Ala Thr Tyr 
20 25 30 
Cys Phe Trp Phe Pro Leu Val Arg Gly Asn Phe Ser Phe Glu Leu Thr 
35 40 45 
Val Asn Tyr Thr Val Cys Pro Pro Cys Leu Thr Arg Gin Ala Ala Ala 
50 55 60 
Glu Ile Tyr Glu Pro Gly Arg Ser Leu Trp Cys Arg Ile Gly His Asp 
70 75 80 65 
Arg Cys Arg Glu Asp Asp His Asp Glu Leu Gly Phe Met Val Pro Pro 
85 90 95 
Gly Leu Ser Ser Glu Gly His Leu Thr Ser Val Tyr Ala Trp Leu Ala 
100 105 110 
Phe Leu Ser Phe Ser Tyr Thr Ala Gin Phe His Pro Glu Ile Phe Gly 
115 120 125 
Ile Gly Asn Val Ser Gin Val Tyr Val Asp Ile Lys His Gln Phe Ile 
130 135 140 
Cys Ala Glu His Asp Gly Gin Asn Ala Thr Leu Pro Arg His Asp Asn 
145 150 155 160 
Ile Ser Ala Val Phe Gin Thr Tyr Tyr Gin His Gin Val Asp Gly Gly 
165 170 175 
Asn Trp Phe His Leu Glu Trp Leu Arg Pro Phe Phe Ser Ser Trp Leu 
180 185 190 
Val Leu Asn Val Ser Trp Phe Leu Arg Arg Ser Pro Ala Ser His Val 
195 200 205 
Ser Val Arg Val Phe Gln Thr Ser Arg Pro Thr Pro Pro Gin Gln Gln 
210 215 220 
Ala Leu Leu Ser Ser Lys Thr Ser Ala Ala Leu Gly Met Ala Thr Arg 
225 230 235 240 
Pro Leu Arg Arg Phe Ala Lys Ala Leu Ser Ala Ala Arg Arg 
245 250 
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< 210 > SEQ ID NO 32 
< 211 > LENGTH : 537 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 32 
atggctgcgc cccttctttt cctcttggtt ggttttaaat gtttcgtggt ttctcaggcg 60 
ttcgcctgca agccatgttt cagttcgagt ctttcagaca tcaagaccaa caccaccgca 120 
gcagcaagct ttgttgtcct ccaagacatc agctgcctta ggcatggcga ctcgtcctct 180 
gaggcgatto gcaaaagctc tcagtgccgc acggcgatag ggacacccgt gtacatcacc 240 
atcacagcca atgtgacaga tgagaattat ttacattctt ctgatctcct catgctttct 300 
tcttgccttt tctatgcttc tgagatgagt gaaaagggat tcaaggtggt atttggcaat 360 
gtgtcaggca tcgtggctgt gtgtgtcaac tttaccagct acgtccaaca tgtcaaggag 420 
tttacccaac gctccttggt ggtcgaccat gtgcggctgc ttcatttcat gacacctgag 480 
accatgaggt gggcaaccgt tttagcctgt ctttttgcca ttctgttggc aatttga 537 
< 210 > SEQ ID NO 33 
< 211 > LENGTH : 178 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 33 
Met Ala Ala Pro Leu Leu Phe Leu Leu Val Gly Phe Lys Cys Phe Val 
1 5 15 10 
Val Ser Gin Ala Phe Ala Cys Lys Pro Cys Phe Ser Ser Ser Leu Ser 
20 25 30 
Asp Ile Lys Thr Asn Thr Thr Ala Ala Ala Ser Phe Val Val Leu Gin 
35 40 45 
Asp Ile Ser Cys Leu Arg His Gly Asp Ser Ser Ser Glu Ala Ile Arg 
50 55 60 
Lys Ser Ser Gin Cys Arg Thr Ala Ile Gly Thr Pro Val Tyr Ile Thr 
65 70 75 80 
Ile Thr Ala Asn Val Thr Asp Glu Asn Tyr Leu His Ser Ser Asp Leu 
85 90 95 
Leu Met Leu Ser Ser Cys Leu Phe Tyr Ala Ser Glu Met Ser Glu Lys 
100 105 110 
Gly Phe Lys Val Val Phe Gly Asn Val Ser Gly Ile Val Ala Val Cys 
115 120 125 
Val Asn Phe Thr Ser Tyr Val Gln His Val Lys Glu Phe Thr Gin Arg 
130 135 140 
Ser Leu Val Val Asp His Val Arg Leu Leu His Phe Met Thr Pro Glu 
145 150 155 160 
Thr Met Arg Trp Ala Thr Val Leu Ala Cys Leu Phe Ala Ile Leu Leu 
165 170 175 
Ala Ile 
< 210 > SEQ ID NO 34 
< 211 > LENGTH : 603 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 34 
atgttgggga aatgcttgac cgcgggctgt tgctcgcgat tgctttcttt gtggtgtatc 60 
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gtgccgttct gttttgctgc gctcgtcaac gccaacagca acagcagctc ccatttacag 120 
ttgatttata acttgacgct atgtgagctg aatggcacag attggctggc taacaaattt 180 
gattgggcag tggagacttt tgtcatcttt cccgtgttga ctcacattgt ctcctatggt 240 
gccctcacca ccagccattt cettgacaca gtcggtctgg tcactgtgtc taccgccggg 300 
ttttatcacg ggcggtatgt cttgagtagc atctacgcgg tctgtgccct ggctgcgttg 360 
atttgcttcg tcattaggtt tgcgaagaac tgcatgtcct ggcgctactc atgtaccaga 420 
tataccaact ttcttctgga cactaagggc agactctatc gttggcggtc gcccgtcatc 480 
atagagaaaa ggggtaaagt tgaggtcgaa ggtcatctga tcgacctcaa aagagttgtg 540 
cttgatggtt ccgtggcaac ccctttaacc agagtttcag cggaacaatg gggtcgtcct 600 
tag 603 
< 210 > SEQ ID NO 35 
< 211 > LENGTH : 200 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 35 
Met Leu Gly Lys Cys Leu Thr Ala Gly Cys Cys Ser Arg Leu Leu Ser 
1 5 10 15 
Leu Trp Cys Ile Val Pro Phe Cys Phe Ala Ala Leu Val Asn Ala Asn 
20 25 30 
Ser Asn Ser Ser Ser His Leu Gin Leu Ile Tyr Asn Leu Thr Leu Cys 
45 35 40 
Glu Leu Asn Gly Thr Asp Trp Leu Ala Asn Lys Phe Asp Trp Ala Val 
55 50 60 
Glu Thr Phe Val Ile Phe Pro Val Leu Thr His Ile Val Ser Tyr Gly 
65 70 75 80 
Ala Leu Thr Thr Ser His Phe Leu Asp Thr Val Gly Leu Val Thr Val 
85 90 95 
Ser Thr Ala Gly Phe Tyr His Gly Arg Tyr Val Leu Ser Ser Ile Tyr 
100 105 110 
Ala Val Cys Ala Leu Ala Ala Leu Ile Cys Phe Val Ile Arg Phe Ala 
115 120 125 
Lys Asn cys Met Ser Trp Arg Tyr Ser Cys Thr Arg Tyr Thr Asn Phe 
130 135 140 
Leu Leu Asp Thr Lys Gly Arg Leu Tyr Arg Trp Arg Ser Pro Val Ile 
145 150 155 160 
Ile Glu Lys Arg Gly Lys Val Glu Val Glu Gly His Leu Ile Asp Leu 
165 170 175 
Lys Arg Val Val Leu Asp Gly Ser Val Ala Thr Pro Leu Thr Arg Val 
180 185 190 
Ser Ala Glu Gln Trp Gly Arg Pro 
195 200 
< 210 > SEQ ID NO 36 
< 211 > LENGTH : 525 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 36 
atggggtcgt cottagacga cttctgccat gatagcacgg ctccacaaaa ggtgcttttg 60 
gcgttttcta ttacctacac gccagtgatg atatatgccc taaaggtaag tcgcggccga 120 
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ctgctagggc ttctgcacct tttgattttt ctgaattgtg ctttcacctt cgggtacatg 180 
acattcgcgc actttcagag cacaaataag gtcgcgctca ctatgggagc agtagttgca 240 
ctcctttggg gggtgtactc agccatagaa acctggaaat tcatcacctc cagatgccgt 300 
ttgtgcttgc taggccgcaa gtacattctg gcccctgccc accacgttga aagtgccgca 360 
ggctttcatc cgattgcggc aaatgataac cacgcatttg tcgtccggcg tcccggctcc 420 
actacggtca acggcacatt ggtgcccggg ttgaaaagcc tcgtgttggg tggcagaaaa 480 
gctgttaaac agggagtggt aaaccttgtc aaatatgcca aataa 525 
< 210 > SEQ ID NO 37 
< 211 > LENGTH : 174 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 37 
Met Gly Ser Ser Leu Asp Asp Phe Cys His Asp Ser Thr Ala Pro Gln 
1 5 10 15 
Lys Val Leu Leu Ala Phe Ser Ile Thr Tyr Thr Pro Val Met Ile Tyr 
20 25 30 
Ala Leu Lys Val Ser Arg Gly Arg Leu Leu Gly Leu Leu His Leu Leu 
35 40 45 
Ile Phe Leu Asn Cys Ala Phe Thr Phe Gly Tyr Met Thr Phe Ala His 
50 55 60 
Phe Gin Ser Thr Asn Lys Val Ala Leu Thr Met Gly Ala Val Val Ala 
65 70 75 80 
Leu Leu Trp Gly Val Tyr Ser Ala Ile Glu Thr Trp Lys Phe Ile Thr 
85 90 95 
Ser Arg Cys Arg Leu Cys Leu Leu Gly Arg Lys Tyr Ile Leu Ala Pro 
100 105 110 
Ala His His Val Glu Ser Ala Ala Gly Phe His Pro Ile Ala Ala Asn 
115 120 125 
Asp Asn His Ala Phe Val Val Arg Arg Pro Gly Ser Thr Thr Val Asn 
130 135 140 
Gly Thr 
145 
al Pro Gly Leu Lys Ser Leu Val Leu Gly Gly Arg Lys 
150 155 160 
Ala Val Lys Gin Gly Val Val Asn Leu Val Lys Tyr Ala Lys 
165 170 
< 210 > SEQ ID NO 38 
< 211 > LENGTH : 372 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 38 
atgccaaata acaacggcaa gcagcagaag aaaaagaagg gggatggcca gccagtcaat 60 
cagctgtgcc agatgctggg taagatcatc goccagcaaa accagtccag aggcaaggga 120 
ccgggaaaga aaaataagaa gaaaaacccg gagaagcccc attttcctct agcgactgaa 180 
gatgacgtca gacatcactt tacccctagt gagcggcaat tgtgtctgtc gtcaatccag 240 
actgccttta atcaaggcgc tggaacttgt accctgtcag attcagggag gataagttac 300 
actgtggagt tta CC gacgcatcat act gcgcc tgatccgcgt cacagcatca 360 
ccctcagcat ga 372 
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< 210 > SEQ ID NO 39 
< 211 > LENGTH : 123 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 39 
Met Pro Asn Asn Asn Gly Lys Gin Gin Lys Lys Lys Lys Gly Asp Gly 
1 5 10 15 
Gin Pro Val Asn Gin Leu Cys Gln Met Leu Gly Lys Ile Ile Ala Gln 
20 25 30 
Gin Asn Gin Ser Arg Gly Lys Gly Pro Gly Lys Lys Asn Lys Lys Lys 
35 45 40 
Asn Pro Glu Lys Pro His Phe Pro Leu Ala Thr Glu Asp Asp Val Arg 
50 55 60 
His His Phe Thr Pro Ser Glu Arg Gin Leu Cys Leu Ser Ser Ile Gln 
65 70 75 80 
Thr Ala Phe Asn Gin Gly Ala Gly Thr Cys Thr Leu Ser Asp Ser Gly 
85 90 95 
Arg Ile Ser Tyr Thr Val Glu Phe Ser Leu Pro Thr His His Thr Val 
100 105 110 
Arg Leu Ile Arg Val Thr Ala Ser Pro Ser Ala 
115 120 
< 210 > SEQ ID NO 40 
< 211 > LENGTH : 156 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 40 
atgttcaagt atgttgggga aatgcttgac cgcgggctgt tgctcgcgat tgctttcttt 60 
gtggtgtatc gtgccgttct gttttgctgc gctcgtcaac gccaacagca acagcagctc 120 
ccatttacag ttgatttaca acttgacgct atgtga 156 
< 210 > SEQ ID NO 41 
< 211 > LENGTH : 51 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 41 
Met Phe Lys Tyr Val Gly Glu Met Leu Asp Arg Gly Leu Leu Leu Ala 
1 5 10 15 
Ile Ala Phe Phe Val Val Tyr Arg Ala Val Leu Phe Cys Cys Ala Arg 
20 25 30 
Gin Arg Gin Gin Gin Gin Gin Leu Pro Phe Thr Val Asp Leu Gin Leu 
35 40 45 
Asp Ala Met 
50 
< 210 > SEQ ID NO 42 
< 211 > LENGTH : 222 
< 212 > TYPE : DNA 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 42 
atgggggcta tgcaaagcct ttttgacaaa attggccaac tttttgtgga tgctttcacg 60 
gaatttttgg tgtccattgt tgatatcatc atatttttgg ccattttgtt tggcttcacc 120 
atcgccggtt ggctggtggt cttttgcatc agattggttt gctccgcggt actccgtgcg 180 
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- continued 
cgccctacca ttcaccctga gcaattacag aagatcctat ga 222 
< 210 > SEQ ID NO 43 
< 211 > LENGTH : 73 
< 212 > TYPE : PRT 
< 213 > ORGANISM : Porcine reproductive and respiratory syndrome virus 
< 400 > SEQUENCE : 43 
Met Gly Ala Met Gln Ser Leu Phe Asp Lys Ile Gly Gin Leu Phe Val 
1 5 10 15 
Asp Ala Phe Thr Glu Phe Leu Val Ser Ile Val Asp Ile Ile Ile Phe 
20 25 30 
Leu Ala Ile Leu Phe Gly Phe Thr Ile Ala Gly Trp Leu Val Val Phe 
35 40 45 
Cys Ile Arg Leu Val Cys Ser Ala Val Leu Arg Ala Arg Pro Thr Ile 
50 55 60 
His Pro Glu Gin Leu Gin Lys Ile Leu 
65 70 
25 What is claimed is : 1. A non - structural PRRSV - CON polypeptide having a 
sequence selected from the group consisting of SEQ ID 
NO : 3 , 5 , and 7 . 
2. The polypeptide of claim 1 , wherein the polypeptide is 
encoded by a nucleic acid , respectively , having a sequence 
selected from the group consisting of SEQ ID NO : 2 , 4 , and 
6 . 
3. A virus particle comprising the non - structural PPRSV 
CON polypeptide of claim 1 . 
4. A composition comprising the virus particle of claim 3 
and a pharmaceutically acceptable carrier . 
5. The composition of claim 4 , further comprising an 
adjuvant . 
6. A composition comprising the non - structural polypep 
tide of claim 1 and a pharmaceutically acceptable carrier . 
7. The composition of claim 6 , further comprising an 
adjuvant . 
8. A method for eliciting an immune response to PPRSV 
in a porcine , comprising administering , to a porcine : 
( i ) an effective amount of the polypeptide of claim 1 ; 
( ii ) an effective amount of the virus particle of claim 3 ; or 
( iii ) an effective amount of the composition of claim 6 . 
30 9. The method of claim 8 , wherein the administration is 
selected from the group consisting of intramuscularly , intra 
peritoneally , and orally . 
10. Amethod for treating or preventing PPRS in a porcine , 
comprising administering , to a porcine : 
( i ) an effective amount of the polypeptide of claim 1 ; 
( ii ) an effective amount of the virus particle of claim 3 ; or 
( iii ) an effective amount of the composition of claim 6 . 
11. The method of claim 10 , wherein the administration is 
selected from the group consisting of intramuscularly , intra 
40 peritoneally , and orally . 
35 
